omcm20170331

Nature of Operations [Text Block]

NOTE

ORGANIZATION AND NATURE OF OPERATIONS

OmniComm Systems, Inc. (“

OmniComm” or the “Company”) is a healthcare technology company that provides web-based electronic data capture (“EDC”) solutions and related value-added services to pharmaceutical and biotech companies, contract research organizations (“CROs”), and other clinical trial sponsors principally located in the United States, Europe and East Asia. Our proprietary EDC software applications; TrialMaster

, TrialOne

, eClinical Suite, and Promasys

(the “EDC Software”) allow clinical trial sponsors and investigative sites to securely collect, validate, transmit and analyze clinical trial data.

Our ability to compete within the EDC industry is predicated on our ability to continue enhancing and broadening the scope of s

olutions offered through our EDC Software and services. Our research and product development efforts are focused on developing new and complementary software solutions, as well as enhancing our existing software solutions through the addition of increased functionality. During the

three

month periods ended

March

31,

2017

and

March

31,

2016

we spent

$778,488

and

$664,605,

respectively, on research and product development activities, which are primarily comprised of salaries to our developers and other research and product development personnel and related costs associated with the development of our software products.

XML 19 R9.htm IDEA: XBRL DOCUMENT

Note 2 - Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2017

Significant Accounting Policies [Text Block]

NOTE

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION

The Company

’s accounts include those of all its wholly-owned subsidiaries, which are more fully described in the Company’s

2016

Annual Report filed on Form

-K with the Securities and Exchange Commission, and have been prepared in conformity with (i) accounting principles generally accepted in the United States of America; and (ii) the rules and regulations of the United States Securities and Exchange Commission. All significant intercompany accounts and transactions between the Company and its subsidiaries have been eliminated in consolidation.

UNAUDITED FINANCIAL STATEMENTS

ncial information, pursuant to the rules and regulations of the Securities and Exchange Commission. Pursuant to such rules and regulations, certain financial information and footnote disclosures normally included in the consolidated financial statements have been condensed or omitted. The results for the

three

month periods ended

March

31,

2017

and

March

31,

2016

are unaudited, but reflect all adjustments (consisting only of normally recurring adjustments) which management considers necessary for a fair presentation of operating results.

The opera

ting results for the

three

month period ended

March

31,

2017

are not necessarily indicative of the results that

may

be expected for the year-ended

December

31,

2017.

These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and footnotes thereto included in the Company’s Annual Report on Form

-K for the year-ended

December

31,

2016.

ESTIMAT

ES IN FINANCIAL STATEMENTS

the financial statements and footnotes thereto. Significant estimates incorporated in our financial statements include the recorded allowance for doubtful accounts, the estimate of the appropriate amortization period of our intangible assets, the evaluation of whether our intangible assets have suffered any impairment, the allocation of revenues under multiple-element customer contracts, royalty-based patent liabilities, the value of derivatives associated with debt issued by the Company and the valuation of any corresponding discount to the issuance of our debt. Actual results

may

differ from those estimates.

Reclassifications

Certain reclassifications have been made in the

2016

financial statements to conform to the

2017

presentation. These reclassifications did not have any effect on our net income/(loss) or shareholders’ deficit.

foreign currency translation

The financial statements of the Company

’s foreign subsidiaries are translated in accordance with Accounting Standards Codification (“ASC”)

830

30,

Foreign Currency Matters—Translation of Financial Statements

("ASC

830

30").

The reporting currency for the Company is the U.S. dollar. The functional currency of the Company’s subsidiaries, OmniComm Europe GmbH in Germany, OmniComm Spain S.L. in Spain and OmniComm Systems B.V. in the Netherlands is the Euro. The functional currency of the Company’s subsidiary, OmniComm Ltd. in the United Kingdom, is the British Pound Sterling. Accordingly, the assets and liabilities of the Company’s foreign subsidiaries are translated into U.S. dollars using the exchange rate in effect at each balance sheet date. Revenue and expense accounts of the Company’s foreign subsidiaries are translated using an average rate of exchange during the period. Foreign currency translation adjustments are accumulated as a component of other comprehensive income/(loss) as a separate component of stockholders’ equity. Gains and losses arising from transactions denominated in foreign currencies are primarily related to intercompany accounts that have been determined to be temporary in nature and accordingly, are recorded directly to the statement of operations. We record translation gains and losses in accumulated other comprehensive income as a component of stockholders’ equity. We recorded translation losses of

$2,468

and

$3,156

for the

three

month periods ended

March

31,

2017

and

March

31,

2016,

respectively.

REVENUE RECOGNITION POLICY

The Company derives revenues from software licenses and services of its EDC products and services whi

ch can be purchased on a stand-alone basis. License revenues are derived principally from the sale of term licenses for the following software products offered by the Company:

TrialMaster, TrialOne

eClinical Suite

and

Promasys.

Service revenues are derived principally from the Company's delivery of the hosted solutions of its

TrialMaster

and

eClinical Suite

software products, and consulting services and customer support, including training, for all of the Company's products.

The Company recognizes revenu

es when all of the following conditions are satisfied:

(1)

there is persuasive evidence of an arrangement;

(2)

the product or service has been provided to the customer;

(3)

the collection of fees is probable; and

(4)

the amount of fees to be paid by the customer is fixed or determinable.

The Company operates in

one

reportable segment which is the delivery of EDC Software and services to clinical trial sponsors. The Company segregates its revenues based on the activity cycle used to generate its revenues.

Accordingly, revenues are currently generated through

four

main activities

, including hosted applications, licensing, professional services and maintenance-related services.

Hosted Application Revenues

The Company offers its

TrialMaster

and

eClinical Suite

software products as hosted application solutions delivered through a standard web-browser, with customer support and training services. The Company's

TrialOne

and

Promasys

solutions are presently available on a technology transfer or off-the shelf basis. To date, hosted applications revenues have been primarily related to

TrialMaster

and

eClinical Suite

Revenues resulting from

TrialMaster

and

eClinical Suite

application hosting services consist of

three

components of services for each clinical trial. The

first

component is comprised of application set up, including design of electronic case report forms and edit checks, installation and server configuration of the system. The

second

component involves application hosting and related support services as well as billable change orders which consist of amounts billed to customers for functionality changes made. The

third

component involves services required to close out, or lock, the database for the clinical trial.

Fees charged for the trial system desig

n, set up and implementation are amortized and recognized ratably over the estimated hosting period. Work performed outside the original scope of work is contracted for separately as an additional fee and is generally recognized ratably over the remaining term of the hosting period. Fees for the

first

and

third

stages of the service are typically billed based upon milestones. Revenues earned upon completion of a contractual milestone are deferred and recognized over the estimated remaining hosting period. Fees for application hosting and related services in the

second

stage are generally billed monthly or quarterly in advance. Revenues resulting from hosting services for the

eClinical Suite

products consist of installation and server configuration, application hosting and related support services. Revenues are recognized ratably over the period of the service.

Licensing Revenues

The Company's software license revenues are earned from the sale of off-the-shelf software. From time-to-time a client might

require significant modification or customization subsequent to delivery to the customer. The Company generally enters into software term licenses for its EDC Software products with its customers for

three

five

year periods, although customers have entered into both longer and shorter term license agreements. These arrangements typically include multiple elements: software license, consulting services and customer support. The Company bills its customers in accordance with the terms of the underlying contract. Generally, the Company bills license fees in advance for each billing cycle of the license term, which typically is either on a quarterly or annual basis. Payment terms are generally net

days.

The

Company has sold perpetual licenses for EDC Software products in certain situations to existing customers with the option to purchase customer support, and

may,

in the future, do so for new customers based on customer requirements or market conditions. The Company has established vendor specific objective evidence of fair value for the customer support. Accordingly, license revenues are recognized upon delivery of the software and when all other revenue recognition criteria are met. Customer support revenues are recognized ratably over the term of the underlying support arrangement. The Company generates customer support and maintenance revenues from its perpetual license customer base.

Professional Services

The Company

may

also enter into arrangements to provide consulting services separate from a li

cense arrangement. In these situations, revenue is recognized on a time-and-materials basis. Professional services can be deemed to be as essential to the functionality of the software at inception and typically are for initial trial configuration, implementation planning, loading of software, building simple interfaces, running test data and documentation of procedures. Subsequent additions or extensions to license terms do not generally include additional professional services.

Pass-through Revenue and

Expense

The Company accounts for pass-through revenue and expense

(reimbursable revenue and reimbursable expense) in accordance with ASC

605

45,

Principal Agent Considerations

(“ASC

605

45”).

In accordance with ASC

605

these amounts are recorded as revenue in the statement of operations with a corresponding expense recorded in cost of goods sold. Pass-through revenues and expenses include amounts associated with

third

-party services provided to our customers by our service and product partners. These

third

-party services are primarily comprised of Interactive Voice and Web Response software services (IVR and IWR), travel and shipping that are incurred on our clients’ behalf.

Maintenance

Revenues

es for both maintenance and software licenses ratably over the term of the software license and support arrangement. The Company allocates the revenues recognized for these arrangements to the different elements based on management's estimate of the relative fair value of each element. The Company generally invoices each of the elements based on separately quoted amounts and thus has a fairly accurate estimate of the relative fair values of each of the invoiced revenue elements.

The fees associated with

each business activity for the

three

month periods ended

March

31,

2017

and

March

31,

2016,

respectively

, are:

	For the three months ended
Revenue activity	March 31, 2017		March 31, 2016
Set-up fees	$	1,381,981	$	1,519,334
Change orders		330,411		277,753
Maintenance		1,219,391		1,201,220
Software licenses		1,964,857		1,200,914
Professional services		559,080		652,320
Hosting		279,810		305,970
Total	$	5,735,530	$	5,157,511

COST

OF GOODS SOLD

Cost of goods sold primarily consists of costs related to hosting, maintaining and supporting the Company

’s application suite and delivering professional services and support. These costs include salaries, benefits, and bonuses for the Company’s professional services staff. Cost of

goods sold

also includes outside service provider costs

Cost of

goods sold

is expensed as incurred.

CASH AND CASH EQUIVALENTS

Cash equivalents consist of highly liquid, short-term investments with maturities of

days

or less. The carrying amount reported in the accompanying consolidated balance sheets approximates fair value.

ACCOUNTS RECEIVABLE

had recorded an allowance for uncollectible accounts receivable of

$209,179

as of

March

31,

2017

and

$179,813

as of

December

31,

2016.

The following table summarizes activity in the Company's allowance for doubtful accounts for the

three

month

period ended

March

31,

2017

and the year ended

December

31,

2016.

	March 31, 2017		December 31, 2016
Beginning of period	$	179,813	$	116,834
Bad debt expense		29,366		132,767
Write-offs		-0-		(69,788	)
End of period	$	209,179	$	179,813

Concentration of Credit Risk

Cash and cash equivalents and restricted cash are deposited with major financial institutions and, at times, such balances with any

one

financial institution

may

be in excess of FDIC-insured limits. As of

March

31,

2017,

$337,346

was deposited in excess of FDIC-insured limits. Management believes the risk in these situations to be minimal.

risk with respect to accounts receivable is limited to creditworthy customers. The Company's customers are principally located in the United States, Europe and East Asia. The Company is directly affected by the overall financial condition of the pharmaceutical, biotechnology and medical device industries and management believes that credit risk exists and that any credit risk the Company faces has been adequately reserved for as of

March

31,

2017.

The Company maintains an allowance for doubtful accounts based on accounts past due according to contractual terms and historical collection experience. Actual losses

, when incurred

, are charged to the allowance. The Company's losses related to collection of accounts receivable have consistently been within management's expectations. As of

March

31,

2017,

the Company believes no additional credit risk exists beyond the amounts provided for in our allowance for uncollectible accounts. The Company evaluates its allowance for uncollectable accounts on a quarterly basis based on a specific review of receivable aging and the period that any receivables are beyond the standard payment terms. The Company does not require collateral from its customers in order to mitigate credit risk.

One customer accounted

for

12%

of our revenues during the

three

month period ended

March

31,

2017

or approximately

$678,000.

One customer accounted for

20%

of our revenues during the

three

month period ended

March

31,

2016

or approximately

$1,037,000.

The following table summarizes the number of customers who individually comprise greater than

10%

of total revenue and/or total accounts receivable and their aggregate percentage of the Company's total revenue and gross accounts receivable for the

three

month periods ended

March

31,

2017

and

March

31,

2016

and the year ended

December

31,

2016.

	Revenues					Accounts receivable
For the period ended	Number of customers		Percentage of total revenues			Number of customers		Percentage of accounts receivable
March 31, 2017		1		12	%		2		30	%
December 31, 2016		1		16	%		2		21	%
March 31, 2016		1		20	%		3		43	%

The table below provides revenues from European customers for the

three

month periods ended

March

31,

2017

and

March

31,

2016.

European revenues
For the three months ended
March 31, 2017					March 31, 2016
European revenues		% of Total revenues			European revenues		% of Total revenues
$	687,209		12	%	$	517,816		10	%

The Company serves all of its hosting customers from

third

-party web hosting facilities located in the United States. The Company does not control the operation of these facilities, and they are vulnerable to damage or interruption. The Company maintains

redundant systems that can be used to provide service in the event the

third

-party web hosting facilities become unavailable, although in such circumstances, the Company's service

may

be interrupted during the transition.

PROPERTY AND EQUIPMENT

Property

and equipment are recorded at cost. Additions and betterments are capitalized; maintenance and repairs are expensed as incurred. Depreciation is calculated using the straight-line method over the asset’s estimated useful life, which is

years for leasehold improvements, computers, equipment and furniture and

years for software. Gains or losses on disposal are charged to operations.

ASSET IMPAIRMENT

Acquisitions and Intangible Assets

We account for acquisitions in accordance with

ASC

805,

Business Combinations

(“ASC

805”)

and

ASC

350,

Intangibles- Goodwill and Other

(“ASC

350”).

The acquisition method of accounting requires that assets acquired and liabilities assumed be recorded at their fair values on the date of a business acquisition. Our consolidated financial statements and results of operations reflect an acquired business from the completion date of an acquisition.

Long-lived Assets

We review long-lived assets for impairment whenever events or changes in circumstances indicate that the related carrying amounts

may

not be recoverable. Determining whether an impairment has occurred typically requires various estimates and assumptions, including determining which cash flows are directly related to the potentially impaired asset, the useful life over which cash flows will occur, their amount and the asset

’s residual value, if any. In turn, measurement of an impairment loss requires a determination of fair value, which is based on the best information available. We use quoted market prices when available and independent appraisals and management estimates of future operating cash flows, as appropriate, to determine fair value.

FAIR VALUE ME

ASUREMENT

OmniComm

’s capital structure includes the use of warrants and convertible debt features that are classified as derivative financial instruments. Derivative financial instruments are recognized as either assets or liabilities and are measured at fair value under ASC

815

Derivatives and Hedging

(“ASC

815”)

ASC

815

requires that changes in the fair value of derivative financial instruments with no hedging designation be recognized as gains/(losses) in the earnings statement. The fair value measurement is determined in accordance with ASC

820

Fair Value Measurements and Disclosures

(“ASC

820”).

DEFERRED REVENUE

Deferred revenue represents cash advances

and amounts in accounts receivable as of the balance sheet date received in excess of revenue earned on on-going contracts. Payment terms vary with each contract but

may

include an initial payment at the time the contract is executed, with future payments dependent upon the completion of certain contract phases or targeted milestones. In the event of contract cancellation, the Company is generally entitled to payment for all work performed through the point of cancellation. As of

March

31,

2017,

the Company had

$9,371,694

in deferred revenues relating to contracts for services to be performed over periods ranging from

one

month to

years. The Company had

$7,304,587

in deferred revenues that are expected to be recognized in the next

twelve

fiscal months.

ADVERTISING

Advertising costs are expensed as incurred. Advertising costs were $

171,268

and

$210,954

for the

three

month periods ended

March

31,

2017

and

March

31,

2016,

respectively, and are included under selling, general and administrative expenses in our unaudited condensed consolidated financial statements.

RESEARCH AND PRODUCT DEVELOPMENT EXPENSES

Software development costs are expensed as incurred.

ASC

985

20,

Software Industry Costs of Software to Be Sold, Leased or Marketed

(“ASC

985

20”),

requires the capitalization of certain development costs of software to be sold once technological feasibility is established, which the Company defines as completion to the point of marketability. The capitalized cost is then amortized on a straight-line basis over the estimated product life. To date, the period between achieving technological feasibility and the general availability of such software has been short and software development costs qualifying for capitalization have been immaterial. Accordingly, the Company has not capitalized any software development costs under ASC

985

20.

During the

three

month periods ended

March

31,

2017

and

March

31,

2016

we spent

$778,488

and

$664,605,

respectively, on research and product development activities, which include costs associated with the development of our software products and services for our clients’ projects and which are primarily comprised of salaries and related expenses for our software developers and consulting fees paid to

third

-party consultants. Research and product development costs are primarily included under Salaries, benefits and related taxes in our Statement of Operations.

EMPLOYEE EQUITY INCENTIVE PLANS

The OmniComm Systems, Inc.

016

Equity Incentive Plan (the

“2016

Plan”) was approved at our Annual Meeting of Shareholders on

June

16,

2016.

The

2016

Plan initially provides for the issuance of up to

10,000,000

shares of our common stock. In addition, the number of shares of common stock available for issuance under the

2016

Plan shall automatically increase on

January

1st

of each year for a period of

nine

(9)

years commencing on

January

2017

and ending on (and including)

January

2025,

in an amount equal to

five

percent

(5%)

of the total number of shares authorized under the

2016

Plan

The predecessor plan

, the OmniComm Systems, Inc.

2009

Equity Incentive Plan (the

“2009

Plan”) was approved at our Annual Meeting of Shareholders on

July

10,

2009

and terminated on

June

16,

2016

upon the approval of the

2016

Plan. The

2009

Plan provided for the issuance of up to

7,500,000

shares to employees, directors and key consultants. The

2016

and

2009

Plans are more fully described in “Note

13,

Employee Equity Incentive Plans”.

The Company accounts for its employee equity incentive plans under

ASC

718,

Compensation – Stock Compensation

, (“ASC

718”)

which addresses the accounting for transactions in which an entity exchanges its equity instruments for goods or services, with a primary focus on transactions in which an entity obtains employee services in share-based payment transactions. ASC

718

requires companies to estimate the fair value of share-based payment awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the Company’s consolidated statements of operations. The Company currently uses the Black Scholes option pricing model to determine grant date fair value.

EARNINGS PER SHARE

The Company accounts for Earnings per Share using

ASC

260,

Earnings per Share

(“ASC

260”)

. Unlike diluted earnings per share basic earnings per share excludes any dilutive effects of options, warrants, and convertible securities.

INCOME TAXES

The Company accounts for income taxes in accordance

with ASC

740,

Income Taxes

(“ASC

740”)

ASC

740

has as its basic objective the recognition of current and deferred income tax assets and liabilities based upon all events that have been recognized in the financial statements as measured by the provisions of the enacted tax laws.

Valuati

on allowances are established

, when necessary

, to reduce deferred tax assets to the estimated amount to be realized. Income tax expense represents the tax payable for the current period and the change during the period in the deferred tax assets and liabilities.

IMPACT OF NEW ACCOUNTING STANDARDS

During the

first

three

months of

2017,

we adopted the following new accounting pronouncements:

No new applicable pronouncements during the

three

month period ended

March

31,

2017.

Accounting standards-setting organizations frequently issue new or revised accounting rules. We

regularly review all new pronouncements to determine their impact, if any, on our financial statements.

XML 20 R10.htm IDEA: XBRL DOCUMENT

Note 3 - Earnings (Loss) Per Share

3 Months Ended

Mar. 31, 2017

Earnings Per Share [Text Block]

NOTE

EARNINGS/

(LOSS) PER SHARE

Basic earnings

/(loss) per share were calculated using the weighted average number of shares outstanding of

147,785,621

and

141,080,292

for the

three

month periods ended

March

31,

2017

and

March

31,

2016,

respectively.

The outstanding share balance as of

March

31,

2017

and

March

31,

2016,

respectively, includes

1,238,350

and

1,703,343

restricted shares that have been issue

d but are still at risk of forfeiture as the restrictions have not lapsed.

Antidilutive shares

47,907,845

and

42,892,652

have been omitted from the calculation of dilutive earnings/(loss) per share for the

three

month periods ended

March

31,

2017

and

March

31,

2016,

respectively, as the shares were antidilutive. Provided below is the reconciliation between numerators and denominators of the basic and diluted earnings per shares. The table below provides a reconciliation of anti-dilutive securities outstanding as of

March

31,

2017

and

March

31,

2016,

respectively.

Anti-dilutive security	March 31, 2017		March 31, 2016
Preferred stock		-0-		135,135
Employee stock options		4,406,905		2,002,500
Warrants		27,860,000		24,690,000
Convertible notes		15,490,000		15,910,000
Shares issuable for accrued interest		150,940		155,017
Total		47,907,845		42,892,652

The employee stock options are exercisable at prices ranging

from

$0.10

$0.25

per share. The exercise prices on the warrants range from

$0.25

$0.60

per share. Shares issuable upon conversion of Convertible Debentures or accrued interest have conversion prices ranging from

$0.25

$1.25

per share.

Some of t

he Company’s convertible debt and convertible preferred stock have an anti-dilutive effect on net income/(loss) per share and were not included in the computation of diluted earnings per share.

	For the three months ended
	March 31, 2017						March 31, 2016
	Income/(loss)		Shares		Per-share		Income/(loss)			Shares		Per-share
	numerator		denominator		amount		numerator			denominator		amount
Basic EPS	$	73,974		147,785,621	$	0.00	$	(878,830	)		141,080,292	$	(0.01	)

Effect of dilutive securities		-0-		168,095		-0-		-0-			-0-		-0-

Diluted EPS	$	73,974		147,953,716	$	0.00	$	(878,830	)		141,080,292	$	(0.01	)

XML 21 R11.htm IDEA: XBRL DOCUMENT

Note 4 - Property and Equipment, Net

3 Months Ended

Mar. 31, 2017

Property, Plant and Equipment Disclosure [Text Block]

NOTE

PROPERTY AND EQUIPMENT, NET

Property and equipment consists of the following:

	March 31, 2017						December 31, 2016
	Cost		Accumulated depreciation		Net book value		Cost		Accumulated depreciation		Net book value		Estimated useful life (years)
Computer & office equipment	$	2,185,356	$	1,805,190	$	380,166	$	2,125,067	$	1,761,879	$	363,188		5
Leasehold improvements		116,841		91,940		24,901		114,719		89,789		24,930		5
Computer software		1,928,685		1,755,575		173,110		1,925,462		1,720,399		205,063		3
Office furniture		159,451		117,072		42,379		158,436		114,065		44,371		5
Total	$	4,390,333	$	3,769,777	$	620,556	$	4,323,684	$	3,686,132	$	637,552

Depreciation expense for the

three

month periods ended

March

31,

2017

and

March

31,

2016

was

$79,924

and

$70,466,

respectively.

XML 22 R12.htm IDEA: XBRL DOCUMENT

Note 5 - Intangible Assets, Net

3 Months Ended

Mar. 31, 2017

Intangible Assets Disclosure [Text Block]

NOTE

INTANGIBLE ASSETS,

NET

Intangible assets consist of the following:

	March 31, 2017						December 31, 2016
Asset	Cost		Accumulated amortization		Net book value		Cost		Accumulated amortization		Net book value		Estimated useful life (years)
eClinical Suite customer lists	$	1,392,701	$	1,392,701	$	-0-	$	1,392,701	$	1,392,701	$	-0-		3
Promasys B.V. customer lists		105,711		24,079		81,632		104,163		21,990		82,173		15
Promasys B.V. software code		72,837		49,772		23,065		72,837		46,130		26,707		5
Promasys B.V. URLs/website		53,389		53,389		-0-		52,608		52,608		-0-		3
Total	$	1,624,638	$	1,519,941	$	104,697	$	1,622,309	$	1,513,429	$	108,880

Amortization expense was $

5,403

and

$10,089

for the

three

month periods ended

March

31,

2017

and

March

31,

2016,

respectively.

Remaining amortization expense for the Company

’s intangible assets is as follows:

2017	$	16,211
2018		19,187
2019		7,047
2020		7,047
2021		7,047
Thereafter		48,158
Total	$	104,697

XML 23 R13.htm IDEA: XBRL DOCUMENT

Note 6 - Accounts Payable and Accrued Expenses

3 Months Ended

Mar. 31, 2017

Accounts Payable and Accrued Liabilities Disclosure [Text Block]

NOTE

ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expenses consist of the following:

Account	March 31, 2017		December 31, 2016
Accounts payable	$	789,898	$	697,060
Accrued payroll and related costs		435,305		886,334
Other accrued expenses		144,986		431,961
Accrued interest		179,579		107,718
Total accounts payable and accrued expenses	$	1,549,768	$	2,123,073

XML 24 R14.htm IDEA: XBRL DOCUMENT

Note 7 - Line of Credit, Notes Payable and Liquidity

3 Months Ended

Mar. 31, 2017

Debt Disclosure [Text Block]

NOTE

LINE

OF CREDIT

NOTES PAYABLE

AND LIQUIDITY

March

18,

2013,

the Company entered into a

$2,000,000

revolving Line of Credit (“

Line of Credit”) with The Northern Trust Company guaranteed by our Chief Executive Officer and Director, Cornelis F. Wit. Mr. Wit receives

2.0%

interest (approximately

$9,500

per month) from the Company on the assets pledged for the Line of Credit. On

December

18,

2013

the Company renewed the Line of Credit and increased the available balance to

$4,000,000.

February

2015

the Company renewed the Line of Credit and increased the available balance to

$5,000,000.

April

2017

the Company renewed the Line of Credit

. The Line of Credit currently matures on

April

2020

and carries a variable interest rate based on the prime rate. At

March

31,

2017,

$2,700,000

was outstanding on the Line of Credit at an interest rate of

.0%.

To satisfy our capital requirements, we

may

seek additional financing. There can be no assurance that any such funding will be available to us on favorable terms or at all. If adequate funds are not available when needed, we

may

be required to delay, scale back or eliminate some or all of our

research and product development and marketing programs. If we are successful in obtaining additional financings, the terms of such financings

may

have the effect of diluting or adversely affecting the holdings or the rights of the holders of our securities or result in increased interest expense in future periods.

March

31,

2017,

the Company owed

$1,242,500

in notes payable all of which are unsecured. The table below provides details as to the terms and conditions of the notes payable.

				Ending		Non related party					Related party
Origination	Maturity	Interest		principal				Long					Long
date	date	rate		March 31, 2017		Current		term			Current		term
2/29/2016	4/1/2019		12%	$	450,000	$	-0-	$	-0-		$	-0-	$	450,000
6/30/2016	4/1/2020		10%		420,000		-0-		420,000			-0-		-0-
6/30/2016	4/1/2020		12%		372,500		-0-		372,500			-0-		-0-
Discount on notes payable							-0-		(420,263	)		-0-		(211,257	)
Total				$	1,242,500	$	-0-	$	372,237		$	-0-	$	238,743

December

31,

2016,

the Company owed

$1,242,500

in notes payable all of which were unsecured. The table below provides details as to the terms and conditions of the notes payable.

				Ending		Non related party					Related party
Origination	Maturity	Interest		principal				Long					Long
date	date	rate		December 31, 2016		Current		term			Current		term
2/29/2016	4/1/2019		12%	$	450,000	$	-0-	$	-0-		$	-0-	$	450,000
6/30/2016	4/1/2020		10%		420,000		-0-		420,000			-0-		-0-
6/30/2016	4/1/2020		12%		372,500		-0-		372,500			-0-		-0-
Discount on notes payable							-0-		(455,285	)		-0-		(237,664	)
Total				$	1,242,500	$	-0-	$	337,215		$	-0-	$	212,336

April

2015

the Company issued a promissory note in the amount of

$20,000

to our Chairman and Chief Technology Officer, Randall G. Smith ("Mr. Smith"),

in exchange for an existing promissory note in the same amount. The promissory note carries an interest rate of

12%

and has a maturity date of

April

2018.

The note was repaid in full on

December

14,

2016.

February

29,

2016,

the Company issued a promissory note in the principal amount of

$450,000

and warrants to purchase

1,8

00,000

shares of common stock of the Company at an exercise price of

$0.25

per share with an expiration date of

April

2019

to our Chief Executive Officer and Director, Cornelis F. Wit (“Mr. Wit”), in exchange for accrued interest in the amount of

$450,000.

The note carries an interest rate of

12%

per annum and has a maturity date of

April

2019.

December

2016

Mr. Wit sold

1,000,000

of the warrants to an employee of the Company.

This issuance caused us to calculate and record a derivative liabili

ty for the warrant liability. The warrants were valued using the Black Scholes option pricing model. A value of

$325,689

was calculated and allocated to the warrants and recorded as a liability to the issuance of the note payable. As a result of the liability we recorded a discount to the note payable. The carrying amount of the note at the time of issuance was therefore

$124,311.

The warrant liability (discount) will be amortized over the

month duration of the note payable. The Company will continue to perform a fair value calculation quarterly on the warrant liability and accordingly the warrant liability is increased or decreased based on the fair value calculation. The resulting increase or decrease is reflected in operations as an unrealized gain or loss on changes in derivative liabilities.

June

30,

2016,

the Company issued promissory notes in the principal amount of

$372,500

and warrants to purchase

1,490,000

shares of common stock of the Company at an exercise price of

$0.25

per share with an e

xpiration date of

April

2020

two

investors, in exchange for existing promissory notes in the same amount. The notes carry an interest rate of

12%

per annum and have a maturity date of

April

2020.

This issuance caused us to calculate and record a derivative liability for the warrant liability. The warrants were valued using the Black Scholes option pricing model. A value of

$246,921

was calculated and allocated to the warrants and record

ed as a liability to the issuance of the note payable. As a result of the liability we recorded a discount to the note payable. The carrying amount of the note at the time of issuance was therefore

$125,579.

The warrant liability (discount) will be amortized over the

month duration of the note payables. The Company will continue to perform a fair value calculation quarterly on the warrant liability and accordingly the warrant liability is increased or decreased based on the fair value calculation. The resulting increase or decrease is reflected in operations as an unrealized gain or loss on changes in derivative liabilities.

June

30,

2016,

the Company issued promissory notes in the principal amount of

$420,000

and warrants to purchase

1,680,000

of common stock of the Company at an exercise price of

$0.25

per share with an expiration date of

April

2020

two

investors, in exchange for existing promissory notes in the same amount. The notes carry an interest rate of

10%

per annum and have a maturity date of

April

2020.

This issuance caused us to calculate and record a derivative liability for the warrant liability. The warrants were valued using the Black Scholes option pricing model. A value of

$278,408

was calculated and allocated to the w

arrants and recorded as a liability to the issuance of the note payable. As a result of the liability we recorded a discount to the note payable. The carrying amount of the note at the time of issuance was therefore

$141,592.

The warrant liability (discount) will be amortized over the

XML 25 R15.htm IDEA: XBRL DOCUMENT

Note 8 - Convertible Notes Payable

3 Months Ended

Mar. 31, 2017

Convertible Debt Disclosure [Text Block]

NOTE

CONVERTIBLE NOTES PAYABLE

The following table summarizes the convertible debt outstanding as of

March

31,

2017

						Carrying amount
Date of	Maturity	Interest		Principal at		Short term				Long term
issuance	date	rate		March 31, 2017		Related		Non related		Related		Non related
8/1/1999	6/30/2004		10%	$	50,000	$	-0-	$	50,000	$	-0-	$	-0-
8/29/2008	4/1/2018		10%		150,000		-0-		-0-		-0-		150,000
8/29/2008	4/1/2020		10%		1,770,000		-0-		-0-		1,770,000		-0-
12/16/2008	4/1/2018		12%		200,000		-0-		-0-		-0-		200,000
12/16/2008	4/1/2020		12%		100,000		-0-		-0-		-0-		100,000
12/16/2008	4/1/2020		12%		4,055,000		-0-		-0-		4,055,000		-0-
9/30/2009	4/1/2018		12%		100,000		-0-		-0-		-0-		100,000
9/30/2009	4/1/2020		12%		625,000		-0-		-0-		-0-		625,000
Total				$	7,050,000	$	-0-	$	50,000	$	5,825,000	$	1,175,000

he following table summarizes the convertible debt outstanding as of

December

31,

2016

						Carrying amount
Date of	Maturity	Interest		Principal at		Short term				Long term
issuance	date	rate		December 31, 2016		Related		Non related		Related		Non related
8/1/1999	6/30/2004		10%	$	50,000	$	-0-	$	50,000	$	-0-	$	-0-
8/29/2008	4/1/2018		10%		150,000		-0-		-0-		-0-		150,000
8/29/2008	4/1/2020		10%		1,770,000		-0-		-0-		1,770,000		-0-
12/16/2008	4/1/2018		12%		200,000		-0-		-0-		-0-		200,000
12/16/2008	4/1/2020		12%		100,000		-0-		-0-		-0-		100,000
12/16/2008	4/1/2020		12%		4,055,000		-0-		-0-		4,055,000		-0-
9/30/2009	4/1/2018		12%		100,000		-0-		-0-		-0-		100,000
9/30/2009	4/1/2020		12%		625,000		-0-		-0-		-0-		625,000
Total				$	7,050,000	$	-0-	$	50,000	$	5,825,000	$	1,175,000

10%

Convertible Notes

During

1999,

the Company issued

10%

Convertible Notes payable in the amount of

$862,500

pursuant to a Confidential Private Placement Memorandum. There were costs of

$119,625

associated with this offering. The net proceeds to the Company were

$742,875.

The notes bear interest at

10%

annually, payable semi-annually. The notes were convertible after maturity, which was

June

30,

2004,

into shares of common stock of the Company at

$1.25

per share. We are in default in the payment of principal and interest. As of

March

31,

2017,

$812,500

of the Convertible Notes had been repaid in cash or converted into

1,495,179

shares of common stock of the Company leaving an outstanding principal balance of

$50,000.

There was

$89,443

of accrued interest at

March

31,

2017.

Secured Convertible Debentures

September

30,

2009,

the Company sold an aggregate of

,400,000

principal amount

12%

Secured Convertible Debentures (the “Debentures”) and common stock purchase warrants (the “Warrants”) to purchase an aggregate of

5,600,000

shares of our common stock exercisable at a price of

$0.25

per share for

four

years subsequent to the closing of the transaction to

four

accredited investors including our Chief Executive Officer and Director, Cornelis F. Wit (“Mr. Wit”). The Company received net proceeds of

$1,400,000.

The Debentures, which bear interest at

12%

per annum, matured on

March

30,

2011.

The Debentures are convertible at any time at the option of the holder into shares of our common stock based upon a conversion rate of

$0.25

per share.

March

30,

2011,

the Company repaid

$200,000

of the outstanding princi

pal amounts owed and extended

$1,200,000

of the convertible notes until

April

2013,

including

$1,100,000

in convertible notes held by Mr. Wit. The Company also extended the expiration date of the warrants associated with the

September

2009

offering to

September

30,

2015.

February

22,

2013,

the Company and

two

holders extended

$1,200,000

of the convertible notes until

January

2016,

including

$1,100,000

in convertible notes held by Mr. Wit.

Mr. Wit also waived all his rights to the security interest under his

$1,100,000

convertible notes.

The expiration date of the warrants associated with the

September

2009

offering was also extended to

January

2016.

January

31,

2015

the Company and Mr. Wit extended the maturity date of

$1,100,000

of conv

ertible debentures to Mr. Wit. The debentures carry an interest rate of

12%

and have a maturity date of

April

2017.

The expiration date of the warrants associated with the debentures was also extended to

April

2017.

November

19,

2015

Mr. Wit converted

$475,000

of the convertible debentures into

1,900,000

shares of our common stock. On

November

19,

2015

the Company and Mr. Wit agreed to cancel the

1,900,000

warrants related to the

$475,000

in convertible debentures and

$475,000

of unrelated promissory notes in exchange for

1,900,000

shares of our common stock. On

November

23,

2015

Mr. Wit sold the remaining

$625,000

of convertible debentures and the related warrants to

two

unrelated non-affiliate shareholders.

April

2015

the Company and the

holder extended the maturity date of

$100,000

of convertible debentures to

April

2018.

The expiration date of the warrants associated with the debentures was also extended to

April

2018.

June

30,

2016

the Company and

two

holders extended the maturity date of

$625,000

of convertible debentures to

April

2020.

The expiration date of the warrants associated with the debentures was also extended to

April

2020.

Convertible Debentures

August

2008

August

29,

2008,

the Company sold

$2,270,000

of convertible debentures and warrants to purchase an aggregate of

4,540,000

shares of our common stock to

four

accredited investors including our Chief Executive Officer and Director, Cornelis F. Wit

(“Mr. Wit”), and

one

of our Directors. The convertible debentures, which bear interest at

10%

per annum, were due on

August

29,

2010.

The convertible debentures are convertible at any time at the option of the holder into shares of our common stock based upon a conversion rate of

$0.50

per share.

September

30,

2009,the

Company and

two

Affiliates of the Company extended

$1,920,000

of the convertible debentures until

August

29,

2013

in accordance with the terms of a Secured Convertible Debenture issued on that date.

The expiration date of the warrants associated with the debentures was also extended to

August

29,

2013.

Feb

ruary

22,

2013

the Company and Mr. Wit extended the maturity date of

$1,770,000

of the convertible debentures to

January

2016.

The expiration date of the warrants associated with the debentures was also extended to

January

2016.

February

22,

201

the Company and Mr. van Kesteren extended the maturity date of

$150,000

of the convertible debentures due to our former Director, Guus van Kesteren (“Mr. van Kesteren”) to

January

2015.

The expiration date of the warrants associated with the debentures was also extended to

January

2015.

April

21,

2014

the Company and Mr. van Kesteren, extended the maturity date of his

$150,000

of convertible debentures to

April

2016.

The expiration date of the warrants associated with the debentures was al

so extended to

April

2016.

July

31,

2014

Mr. van Kesteren’s term on the Board of Directors ended. Effective on the same date, his convertible note in the amount of

$150,000

was reclassified from Related Party to Non-Related Party.

January

31,

the Company and Mr. Wit extended the maturity date of the

$1,770,000

of convertible debentures to

April

2017.

The expiration date of the warrants associated with the debentures was also extended to

April

2017.

June

30,

2015

the Company and M

r. van Kesteren extended the maturity date of

$150,000

of convertible debentures to

April

2017.

The expiration date of the warrants associated with the debentures was also extended to

April

2017.

On Ju

30,

2016

the Company and Mr. Wit extended the maturity date of the

$1,770,000

of convertible debentures to

April

2020.

The expiration date of the warrants associated with the debentures was also extended to

April

2020.

June

30,

201

the Company and Mr. van Kesteren extended the maturity date of

$150,000

of convertible debentures to

April

2018.

The expiration date of the warrants associated with the debentures was also extended to

April

2018.

December

2008

December

16,

2008,

the Company sold

$5,075,000

of convertible debentures and warrants to purchase an aggregate of

10,150,000

shares of common stock to

eleven

accredited investors including our Chief Executive Officer and Director, Cornelis F. Wit (“Mr. Wit”), our Chief Operating Officer and President, Stephen E. Johnson (“Mr. Johnson”), our Chairman and Chief Technology Officer, Randall G. Smith (“Mr. Smith”), our Chief Financial Officer, Ronald T. Linares, and

four

of our Directors. The convertible debentures, which bear interest at

12%

per annum, were due on

December

16,

2010.

The convertible debentures are convertible at any time at the option of the holder into shares of our common stock based upon a conversion rate of

$0.50

per share.

September

30,

2009

Affiliates of the Compan

y extended

$4,980,000

of Convertible Notes until

December

16,

2013

in accordance with the terms of a Secured Convertible Debenture issued on that date. The expiration date of the warrants associated with the debentures was also extended to

December

13,

2013.

February

22,

2013

the Company and the

holders agreed to extend the maturity date of

$4,505,000

of the convertible debentures including

$4,475,000

due to Mr. Wit,

$25,000

due to Mr. Johnson, and

$5,000

due to Mr. Smith, to

January

2016.

The expiration date of the warrants associated with the debentures was also extended to

January

2016.

On Febru

ary

27,

2013

the Company and Mr. Veatch extended the maturity date of

$15,000

of convertible debentures issued to our former Director, Matthew Veatch, to

January

2016.

The expiration date of the warrants associated with the debentures was also extended to

January

2016.

March

2013,

the Company and

one

of the

holders agreed to extend the maturity date of

$200,000

of convertible debentures to

January

2014.

The expiration date of the warrants associated with the debentures was also extended to

January

2014.

March

12,

2013,

the Company and

one

of the

holders agreed to extend the maturity date of

$100,000

of convertible debentures to

January

2015.

The expiration date of the warrants associated with the debentures was also extended to

January

2015.

December

2013,

the Company and

two

holders agreed to extend the maturity date of

$360,000,

including

$160,000

due to our former Director, Guus van Kesteren (“Mr. van Kesteren”), of convertible debentures to

January

2016.

The expiration date of the warrants associated with the debentures was also extended to

January

2016.

July

31,

2014

Mr. van Kesteren’s term on the Board of Directors ended. Effective on the same date, his convertible note in the amount of

$160,000

was reclassified from Related Party to Non-Related Party.

April

28,

2014

the Company and the

holder extended the maturity date of

$100,000

of convertible debentures to

April

2016.

The expiration date of the warrants associated with the debentures was also extended to

April

2016.

January

31,

2015

the Company and Mr. Wit extended the maturity date of

$4,475,000

of convertible debentures to Mr. Wit

April

2017.

The expiration date of the warrants associated with the debentures was also extended to

April

2017.

November

19,

2015

the Company and Mr. Wit agreed to cancel

$420,000

of the debentures and

1,680,000

of unrelated warrants in exchange for

1,680,000

shares of our common stock.

April

27,

2015,

the Company and the

holder extended the maturity date of

$200,000

of convertible debentures to

April

2018.

The expiration date of the warrants associated with the debentures was also extended to

April

2018.

April

30,

2015,

the Company and Mr. Johnson extended the maturity date of

$25,000

of convertible debentures to

April

2018.

The expiration date of the warrants associated with the debentures was also extended to

April

2018.

The convertible debentures were repaid in full on

December

14,

2016.

May

2015

the Company and Mr. van

Kesteren extended the maturity date of

$160,000

of convertible debentures to

April

2017.

The expiration date of the warrants associated with the debentures was also extended to

April

2017.

May

2015

the Company

paid

$5,000

to Mr. Smith in exchange for

$5,000

of convertible debentures originally issued in

December

2008.

May

2015

the Company and our former Director, Matthe

w Veatch, extended the maturity date of

$15,000

of convertible debentures to

April

2018.

The expiration date of the warrants associated with the debentures was also extended to

April

2018.

The convertible debentures were repaid in full on

December

14,

2016.

June

30,

2015

the Company and the

holder extended the maturity date of

$100,000

of convertible debentures to

April

2017.

The expiration date of the warrants associated with the debentures was also extended to

April

2017.

On J

une

30,

2016

the Company and Mr. Wit extended the maturity date of

$4,055,000

of convertible debentures to Mr. Wit to

April

2020.

The expiration date of the warrants associated with the debentures was also extended to

April

2020.

June

30,

2016

the Company and Mr. van Kesteren extended the maturity date of

$160,000

of convertible debentures to

April

2018.

The expiration date of the warrants associated with the debentures was also extended to

April

2018.

The convertible debentures were repaid in full on

December

14,

2016.

June

30,

2016

the Company and the holder extended the maturity date of

$100,000

of convertible debentures to

April

2020.

The expiration date of the warrants associated with the debentures was also extended to

April

2020.

The

principal payments required at maturity under the Company’s outstanding convertible debt at

March

31,

2017

are as follows:

2017	$	50,000
2018		450,000
2019		-0-
2020		6,550,000
Total	$	7,050,000

XML 26 R16.htm IDEA: XBRL DOCUMENT

Note 9 - Fair Value Measurement

3 Months Ended

Mar. 31, 2017

Fair Value Disclosures [Text Block]

NOTE

FAIR VALUE MEASUREMENT

The Company measures the fair value of its assets and liabilities under the guidance of

ASC

820,

Fair Value Measurements and Disclosures

("ASC

820"),

which defines fair value, establishes a framework for measuring fair value in accordance with generally accepted accounting principles and expands disclosures about fair value measurements. ASC

820

does not require any new fair value measurements, but its provisions apply to all other accounting pronouncements that require or permit fair value measurement.

ASC

820

clarifies that fair value is an exit price, representing the price that would be received to sell an asset or paid to transfer a liability in an

orderly transaction between market participants based on the highest and best use of the asset or liability. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. ASC

820

requires the Company to use valuation techniques to measure fair value that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized as follows:

	●	Level 1 : Observable inputs such as quoted prices for identical assets or liabilities in active markets;

	●	Level 2 : Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly such as quoted prices for similar assets or liabilities or market-corroborated inputs; and

●

Level

: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions about how market participants would price the assets or liabilities.

The valuation techniques that

may

be used to measure fair value are as follows:

Market approach

- Uses prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities

Income approach

- Uses valuation techniques to convert future amounts to a single present amount based on current market expectations about those future amounts, including present value techniques, option-pricing models and excess earnings methods

Cost approach

- Based on the amount that currently would be required to replace the service capacity of an asset (replacement cost)

The Company also adopted the provisions of

ASC

825,

Financial Instruments

(“ASC

825”).

ASC

825

allows companies to choose to measure eligible assets and liabilities at fair value with changes in value recognized in earnings. Fair value treatment

may

be elected either upon initial recognition of an eligible asset or liability or, for an existing asset or liability, if an event triggers a new basis of accounting. The Company did not elect to re-measure any of its existing financial assets or liabilities under the provisions of this Statement. The Company elected the fair value option for the issuance of warrants associated with the promissory notes issued in the

three

month period ended

March

31,

2016.

The Company

’s financial assets or liabilities subject to ASC

820

as of

March

31,

2017

include the conversion feature and warrant liability associated with convertible debentures issued during

2008

and

2009

and the warrants issued during

2011

and

2016

that are associated with notes payable. The conversion feature and warrants were deemed to be derivatives (the “Derivative Instruments”) since a fixed conversion price cannot be determined for either of the Derivative Instruments due to anti-dilution provisions embedded in the offering documents for the convertible debentures. The derivative instruments were not issued for risk management purposes and as such are not designated as hedging instruments under the provisions of ASC

815

Disclosures about Derivative Instruments and Hedging Activities

. See Note

– Convertible Notes Payable.

Following is a description of the valuation methodologies used to determine the fair value of the Company

’s financial liabilities including the general classification of such instruments pursuant to the valuation hierarchy.

A summary as of

March

31,

2017

of the fair value of liabilities measured at fair value on a recurring basis follows:

	Fair value at		Quoted prices in active markets for identical assets/ liabilities		Significant other observable inputs		Significant unobservable inputs
	March 31, 2017		(Level 1)		(Level 2)		(Level 3)
Derivatives: (1) (2)
Conversion feature liability	$	2,134,868	$	-0-	$	-0-	$	2,134,868
Warrant liability		3,796,884		-0-		-0-		3,796,884
Total of derivative liabilities	$	5,931,752	$	-0-	$	-0-	$	5,931,752

(1)

The fair value of the derivative instruments was estimated using the Income Approach and the Black Scholes option pricing model with the following assumptions for the

three

month period ended

March

31,

2017

(2)

The fair value at the measurement date is equal to the carrying value on the balance sheet

Significant valuation assumptions for derivative instruments at March 31, 2017
Risk free interest rate	0.82%	to	1.47%
Dividend yield		0.00%
Expected volatility	110.9%	to	129.9%
Expected life (range in years)
Conversion feature liability	1.00	to	3.01
Warrant liability	0.00	to	3.01

A summary as of

December

31,

2016

of the fair value of liabilities measured at fair value on a recurring ba

is follows:

	Fair value at		Quoted prices in active markets for identical assets/ liabilities		Significant other observable inputs		Significant unobservable inputs
	December 31, 2016		(Level 1)		(Level 2)		(Level 3)
Derivatives: (1) (2)
Conversion feature liability	$	2,325,730	$	-0-	$	-0-	$	2,325,730
Warrant liability		3,999,362		-0-		-0-		3,999,362
Total of derivative liabilities	$	6,325,092	$	-0-	$	-0-	$	6,325,092

(1)

The fair value of the derivative instruments was estimated using the Income Approach and the Black Scholes option pricing model with the following assumptions for the year ended

December

31,

2016

(2)

The fair value at the measurement date is equal to the carrying value on the balance sheet

Significant valuation assumptions for derivative instruments at December 31, 2016
Risk free interest rate	0.82%	to	1.45%
Dividend yield		0.00%
Expected volatility	117.3%	to	143.8%
Expected life (range in years)
Conversion feature liability	1.25	to	3.25
Warrant liability	0.25	to	3.25

A summary as of

March

31,

2017

and

December

31,

2016

of the fair value of assets measured at fair value on a non-recurring

basis follows:

	Carrying amount		Carrying amount		Quoted prices in active markets for identical assets/ liabilities		Significant other observable inputs		Significant unobservable inputs
	December 31, 2016		March 31, 2017		(Level 1)		(Level 2)		(Level 3)
Acquired assets (3)
Promasys B.V. customer list (4)	$	82,173	$	81,632	$	-0-	$	-0-	$	136,253
Promasys B.V. software code (4)		26,707		23,065		-0-		-0-		72,943
Promasys B.V. URLs/website (4)		-0-		-0-		-0-		-0-		68,814
Total	$	108,880	$	104,697	$	-0-	$	-0-	$	278,010

(3)

The fair value of the acquired assets was estimated using the Income Approach with a discounted cash flow valuation methodology applied.

(4)

The acquired Promasys B.V. software code, customer list and URLs/website are not measured on a recurring basis since their initial fair value has been deemed to have a finite life and is being amortized periodically. Instead the Company performs an impairment analysis on a quarterly basis in order to determine whether the carrying value of the assets reflects the fair value of the assets in a market based transaction.

Other identifiable intangible assets, which are subject to amortization, are being amortized using the straight-line method over their estimated useful lives ranging from

years. The Impairment or Disposal of Long-Lived Asset subsection of

ASC

360,

Property, Plant and Equipment

requires us to test the recoverability of long-lived assets, including identifiable intangible assets with definite lives, whenever events or changes in circumstances indicate that the carrying amount

may

not be recoverable. In testing for potential impairment, if the carrying value of the asset group exceeds the expected undiscounted cash flows, we must then determine the amount by which the fair value of those assets exceeds the carrying value and determine the amount of impairment, if any.

The table below presents the

unrealized gains/(losses) for the

three

month periods ended

March

31,

2017

and

March

31,

2016

	Other income/(expense)
	For the three months ended
	March 31, 2017		March 31, 2016
The net amount of gains/(losses) for the period included in earnings attributable to the unrealized and realized gain/(losses) from changes in derivative liabilities at the reporting date	$	393,340	$	(762,011	)

Total unrealized and realized gains/(losses) included in earnings	$	393,340	$	(762,011	)

The tables below set forth a

summary of changes in fair value of the Company’s Level

financial liabilities at fair value for the

three

month period ended

March

31,

2017

and the year ended

December

31,

2016.

The tables reflect changes for all financial liabilities at fair value categorized as Level

as of

March

31,

2017

and

December

31,

2016.

	Level 3 financial liabilities at fair value
								Net
								purchases,
	Balance,							issuances				Balance,
For the three months ended	beginning			Net realized		Net unrealized		and		Net transfers		end
March 31, 2017	of year			gains/(losses)		gains/(losses)		settlements		in and/or out		of period
Derivatives:
Conversion feature liability	$	(2,325,730	)	$	-0-	$	190,862	$	-0-	$	-0-	$	(2,134,868	)
Warrant liability		(3,999,362	)		-0-		202,478		-0-		-0-		(3,796,884	)
Total of derivative liabilities	$	(6,325,092	)	$	-0-	$	393,340	$	-0-	$	-0-	$	(5,931,752	)

	Level 3 financial liabilities at fair value
									Net
									purchases,
	Balance,								issuances					Balance,
For the year ended	beginning			Net realized		Net unrealized			and			Net transfers		end
December 31, 2016	of year			gains/(losses)		gains/(losses)			settlements			in and/or out		of year
Derivatives:
Conversion feature liability	$	(901,243	)	$	29,108	$	(1,453,595	)	$	-0-		$	-0-	$	(2,325,730	)
Warrant liability		(1,914,923	)		-0-		(1,233,423	)		(851,016	)		-0-		(3,999,362	)
Total of derivative liabilities	$	(2,816,166	)	$	29,108	$	(2,687,018	)	$	(851,016	)	$	-0-	$	(6,325,092	)

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 27 R17.htm IDEA: XBRL DOCUMENT

Note 10 - Commitments and Contingencies

3 Months Ended

Mar. 31, 2017

Commitments and Contingencies Disclosure [Text Block]

NOTE

10:

COMMITMENTS AND CONTINGENCIES

The Company currently leases office space under operating leases for its office locations and has operating leases related to

server and network co-location and disaster recovery for its operations. The minimum future lease payments required under the Company’s operating leases at

March

31,

2017

are as follows:

2017	$	566,546
2018		566,119
2019		421,230
2020		297,570
2021		269,962
Thereafter		310,550
Total	$	2,431,977

In addition to annual base rental payments, the Company pays for the operating expenses associated with its leased

office space and is responsible for any escalation in operating expenses as determined in the leases. Rent expense was

$278,952

and

$256,600

for the

three

month periods ended

March

31,

2017

and

March

31,

2016,

respectively.

The Company

’s Fort Lauderdale, Florida corporate office lease expires in

February

2023

. The Company’s lease on its New Jersey field office expires in

March

2021.

The Company currently operates its wholly-owned subsidiary, OmniComm Ltd., in the United Kingdom under the terms of a lease that expires in

September

2017.

The Company currently operates its wholly-owned subsidiary, OmniComm Europe, GmbH, in Germany under the terms of a lease that expires in

July

2017

. The Company currently operates its wholly-owned subsidiary, OmniComm Systems B.V, in the Netherlands under the terms of a lease that expires in

October

2018.

LEGAL PROCEEDINGS

From time to time the Company

may

be involved in litigation relating to claims arising out of our operations in the normal course of business. As of

March

31,

2017,

there were

pending or threatened lawsuits that could reasonably be expected to have a material effect on the results of our operations.

PATENT LITIGATION SETTLEMENT

Effective

April

2009,

we entered into a Settlement and License Agreement with DataSci, LLC (“DataSci”). DataSci granted us a worldwide, non-exclusive non-transferable right and license under the Licensed Patent and the right to sublicense TrialMaster on a Technology Transfer and Technology Transition basis. Under the terms of the Settlement and License Agreement, as amended, we are obligated to pay royalties quarterly for sales of Licensed Products, as defined therein, from

January

2009

until the termination of the Settlement and License Agreement on

December

31,

2017

equal to

two

percent

(2%)

of OmniComm’s annual Gross Revenues or, alternatively, the annual minimum royalty payment(s), whichever is greater. In addition to the payment of royalties, the Settlement and Licensing Agreement imposes certain obligations on us including commercialization, certain sublicensing, other payments, insurance, and confidentiality. In addition and as a license fee for past use of the Licensed Patent which

may

have occurred prior to the effective date of the Settlement and Licensing Agreement, we issued a warrant to DataSci to purchase

1,000,000

shares of our common stock at an exercise price of

$.01

per share. The Settlement and Licensing Agreement provides that upon the expiration date of the warrant, at DataSci’s sole discretion, DataSci shall exercise its option under the warrant or licensee shall pay DataSci

$300,000.

The warrant is exercisable commencing on the

second

anniversary of the Settlement and Licensing Agreement,

April

2011,

through the expiration date of the warrant, on the termination date of the Settlement and Licensing Agreement on

December

31,

2017.

June

23,

2009,

we entered into an agreement to acquire the EDC assets of eResearch Technology. Concurrent with the consummation of that transaction we entered into the First Amendment to Settlement and Licensing Agreement with DataSci, (i) to include the eResearch Technology EDC assets acquired within the definition of Licensed Products, and as such subject to the royalty payment(s), under and in accordance with the Settlement and Licensing Agreement, and (ii) provide a release by DataSci of any and all claims of infringement of the Licensed Patent in connection with the eResearch Technology EDC assets acquired which

may

have occurred prior to the effective date of the First Amendment to Settlement and Licensing Agreement for an aggregate amount of

$300,000.

The remaining minimum royalty payments per year are as follows:

2017		$	450,000
Total		$	450,000

During the

three

month periods ended

March

31,

2017

and

March

31,

2016

the Company recorded a charge to earnings of

($127,983)

and

$27,437

respectively, which amounts represent (i) the amount of additional license expense incurred above the stipulated minimum in the DataSci Settlement and License Agreement during the

three

month periods ended

March

31,

2017

and

March

31,

2016

and (ii) the accretion of the difference between the total stipulated annual minimum royalty payments and the recorded present value accrual of the annual minimum royalty payments.

EMPLOYMEN

T AGREEMENTS

We have employment agreements in place with the

following members of our executive management team:

Cornelis F. Wit, Chief Executive

Officer

Randall

G. Smith, Chief Technology Officer

Stephen

E. Johnson, President and Chief Operating Officer

Thomas E. Vickers, Chief Financial Officer

The

employment agreements provide, among other things, for participation in employee benefits available to employees and executives. Each of the agreements will renew for successive

one

-year terms unless the agreement is expressly terminated by either the employee or the Company prior to the end of the then current term as provided for in the employment agreement. Under the terms of the agreement, we

may

terminate the employee’s employment upon

days notice of a material breach and the employee

may

terminate the agreement under the same terms and conditions. The employment agreements contain non-disclosure provisions, as well as non-compete clauses. The agreements for Mr. Smith, Mr. Johnson and Mr. Vickers contain severance provisions

which entitles the employee to severance pay equal to

one

(1)

year's

salary and benefits in the event of the employee's termination by us for any reason other than for cause, as described in the employment agreement, or termination by the employee pursuant to a material breach of the agreement by us.

XML 28 R18.htm IDEA: XBRL DOCUMENT

Note 11 - Related Party Transactions

3 Months Ended

Mar. 31, 2017

NOTE

RELATED PARTY

TRANSACTIONS

April

2015

the Company issued a promissory note in the amount of

$20,000

to our Chairman and Chief Technology Officer, Randall G. Smith (“

Mr. Smith”), in exchange for an existing promissory note in the same amount. The promissory note carries an interest rate of

12%

and has a maturity date of

April

2018.

The note was repaid in full on

December

14,

2016.

April

30,

2015,

the Company and Stephen E. Johnson, our Chief Operating Officer and President (“

Mr. Johnson”) extended the maturity date of

$25,000

of convertible debentures to Mr. Johnson, originally issued in

December

2008.

The debentures carry an interest rate of

12%

and have a maturity date of

April

2018.

The expiration date of the warrants associated with the debentures was also extended to

April

2018.

The convertible debentures were repaid in full on

December

14,

2016.

As of

March

31,

2017,

we have an aggregate of

$5,825,000

of convertible debentures and

$450,000

of promissory notes outstanding to our Chief Executive Officer and Director, Cornelis F. Wit (“Mr. Wit”), and have issued certain warrants to Mr. Wit, as follows:

●

June

2008,

Mr. Wit invested

$510,000

in convertible notes. On

August

29,

2008,

Mr. Wit converted the

$510,000

and invested an additional

$1,260,000

in a private placement of convertible debentures and warrants to purchase

3,540,000

shares of our common stock. The convertible debentures, which bear interest at

10%

per annum, were due on

August

29,

2010.

The convertible debentures are convertible at any time at the option of the holder into shares of our common stock based upon a conversion rate of

$0.50

per share. On

September

30,

2009,

the Company and Mr. Wit extended the

$1,770,000

of convertible debentures until

August

29,

2013

in accordance with the terms of a Secured Convertible Debenture issued on that date. The expiration date of the warrants associated with the debentures was also extended to

August

29,

2013.On

February

22,

2013,

the Company and Mr. Wit extended the maturity date of the

$1,770,000

of convertible debentures to

January

2016.

The expiration date of the warrants associated with the debentures was also extended to

January

2016.

January

31,

2015

the Company and Mr. Wit extended the maturity date of the

$1,770,000

of convertible debentures to

April

2017.

The expiration date of the warrants associated with the debentures was also extended to

April

2017.

June

30,

2016

the Company and Mr. Wit extended the maturity date of the

$1,770,000

of convertible debentures to

April

2020.

The expiration date of the warrants associated with the debentures was also extended to

April

2020

●

February

2008,

Mr. Wit invested

$150,000

in promissory notes and from

September

2008

December

2008,

Mr. Wit invested

$4,200,000

in convertible notes. On

December

16,

2008,

Mr. Wit converted the

$4,350,000

into a private placement of convertible debentures and warrants to purchase

8,700,000

shares of our common stock. The convertible debentures, which bear interest at

12%

per annum, were due on

December

16,

2010.

The convertible debentures are convertible at any time at the option of the holder into shares of our common stock based upon a conversion rate of

$0.50

per share. On

September

30,

2009,

the Company and Mr. Wit extended the

$4,350,000

of convertible debentures until

December

16,

2013

in accordance with the terms of a Secured Convertible Debenture issued on that date. The expiration date of the warrants associated with the debentures was also extended to

December

16,

2013,

2013.

In a private transaction on

October

16,

2012,

Mr. Wit purchased

$125,000

of the

December

2008

convertible debentures and the related

250,000

warrants from Mr. Ronald Linares, the Company’s former Chief Financial Officer. On

February

22,

2013,

the Company and Mr. Wit extended the maturity date of the

$4,475,000

of convertible debentures to

January

2016.

The expiration date of the warrants associated with the debentures was also extended to

January

2016.

January

31,

2015

the Company and Mr. Wit extended the maturity date of the

$4,475,000

of convertible debentures to

April

2017.

The expiration date of the warrants associated with the debentures was also extended to

April

2017.

November

19,

2015

the Company and Mr. Wit agreed to cancel

$420,000

of the debentures and

1,680,000

of unrelated warrants in exchange for

1,680,000

shares of our common stock. On

June

30,

2016

the Company and Mr. Wit extended the maturity date of the

$4,055,000

of convertible debentures to

April

2020.

The expiration date of the warrants associated with the debentures was also extended to

April

2020

●

February

29,

2016,

the Company issued a promissory note in the principal amount of

$450,000

and warrants to purchase

1,800,000

shares of common stock of the Company at an exercise price of

$0.25

per share with an expiration date of

April

2019

to Mr. Wit in exchange for accrued interest in the amount of

$450,000.

The note carries an interest rate of

12%

per annum and has a maturity date of

April

2019.

March

18,

2013,

the Company enter

ed into a

$2,000,000

revolving Line of Credit (“Line of Credit”) with The Northern Trust Company guaranteed by our Chief Executive Officer and Director

, Cornelis F. Wit. Mr. Wit receives

2.0%

interest (approximately

$9,500

per month) from the Company on the assets pledged for the Line of Credit. On

December

18,

2013

the Company renewed the Line of Credit and increased the available balance to

$4,000,000.

February

2015

the Company renewed the Line of Credit and increased the available balance to

$5,000,000.

April

2017

the Company renewed the Line of Credit. The Line of Credit currently matures on

April

2020

and carries a variable interest rate based on the prime rate. At

March

31,

2017,

$2,700,000

was outstanding on the Line of Credit at an interest rate of

3.0%.

For the

three

month periods ended

March

31,

2017

and

March

31,

2016

we incurred

$231,459

and

$208,602,

respectively, in interest expense payable to related parties.

XML 29 R19.htm IDEA: XBRL DOCUMENT

Note 12 - Stockholders' (Deficit)

3 Months Ended

Mar. 31, 2017

Stockholders' Equity Note Disclosure [Text Block]

NOTE

STOCKHOLDERS’ (DEFICIT)

Our authorized capital

stock consists of

500,000,000

shares of common stock,

$.001

par value per share, and

10,000,000

shares of preferred stock, par value

$.001

per share, of which

5,000,000

shares have been designated as

Series A Preferred Stock,

230,000

shares have been designated as Series B Preferred Stock,

747,500

shares have been designated as Series C Preferred Stock and

250,000

shares have been designated as Series D Preferred Stock.

At the

2016

Annual Meeting of Stockholders the

proposed amendment to the Company’s Certificate of Incorporation to increase the authorized number of shares of common stock by

250,000,000

shares to an aggregate of

500,000,000

shares received an affirmative vote from the holders of a majority of the outstanding shares of Voting Securities and an affirmative vote from the holders of a majority of the outstanding shares of common stock. Based on the votes received, the proposed amendment was approved and the number of authorized shares of common stock of the Company was increased from

250,000,000

shares to

500,000,000

shares.

As of

March

31,

2017

we had the following outstanding securities:

	o	147,770,249 shares of common stock issued and outstanding;
	o	27,860,000 warrants issued and outstanding to purchase shares of our common stock;
	o	4,575,000 options issued and outstanding to purchase shares of our common stock
	o	- 0 - shares of our Series A Preferred Stock issued and outstanding;
	o	- 0 - shares of our Series B Preferred Stock issued and outstanding;
	o	- 0 - shares of our Series C Preferred Stock issued and outstanding;
	o	250,000 share of our Series D Preferred Stock issued and outstanding; and
	o	$7,050,000 principal amount Convertible Debentures convertible into 15,490,000 shares of common stock.

Common Stock

Holders of common stock are entitled to

one

vote for each share on all matters submitted to a stockholder vote. Holders of our voting securities do not have cumulative voting right

s. Holders of common stock are entitled to share in all dividends that the Board of Directors, in its discretion, declares from legally available funds. In the event of our liquidation, dissolution or winding up each outstanding share of common stock entitles its holder to participate in all assets that remain after payment of liabilities and after providing for each class of stock, if any, having preference over the common stock.

Holders of common stock have no conversion, preemptive or other subscription

rights, and there are no redemption provisions for the common stock. The rights of the holders of common stock are subject to any rights that

may

be fixed for holders of preferred stock, when and if any preferred stock is outstanding. All outstanding shares of common stock are duly authorized, validly issued, fully paid and non-assessable.

Preferred

tock

Our Board of Directors, without further stockholder approval,

may

issue preferred stock in

one

or more series from time to time and fix or alter the de

signations, relative rights, priorities, preferences, qualifications, limitations and restrictions of the shares of each series. In addition, the Board of Directors

may

fix and determine all privileges and rights of the authorized preferred stock series including:

	o	dividend and liquidation preferences;
	o	voting rights;
	o	conversion privileges; and
	o	redemption terms.

Our Board of Directors

may

authorize the issuance of preferred stock which ranks senior to our common stock for the payment of dividends and the

distribution of assets on liquidation. In addition, our Board of Directors can fix limitations and restrictions, if any, upon the payment of dividends on our common stock to be effective while any shares of preferred stock are outstanding.

During the peri

od from

December

2015

through

April

2016

all

Series A Preferred Stock shareholders accepted the Company's Exchange Offer and converted a total of

4,125,224

Series A preferred shares into

16,565,696

common shares.

The following table presents the cumulative

arrearage of undeclared dividends by class of preferred stock as of

March

31,

2017

and

March

31,

2016,

respectively, and the per share amount by class of preferred stock.

	Cumulative arrearage as of				Cumulative arrearage per share as of
	March 31,				March 31,
Series of preferred stock	2017		2016		2017		2016

Series A	$	-0-	$	102,526	$	-0-	$	0.68
Series B		609,887		609,887	$	3.05	$	3.05
Series C		1,472,093		1,472,093	$	4.37	$	4.37
Total preferred stock arrearage	$	2,081,980	$	2,184,506

The following table presents preferred dividends accreted for the

three

month periods ended

March

31,

2017

and

March

31,

2016,

respectively, and the per share effect of the preferred dividends if their effect was not anti-dilutive.

	Dividends accreted				Dividends per share
	For the three months ended				For the three months ended
	March 31,				March 31,
	2017		2016		2017		2016
Preferred stock dividends in arrears Series A	$	-0-	$	1,870	$	-0-	$	0.012
Preferred stock dividends in arrears Series B	$	-0-	$	-0-	$	-0-	$	-0-
Preferred stock dividends in arrears Series C	$	-0-	$	-0-	$	-0-	$	-0-

Warrants Issued for

Services and in Capital Transactions

The following tables summarize all

outstanding warrants for the

three

month period ended

March

31,

2017

and the year ended

December

31,

2016,

and the related changes during these periods.

March 31, 2017									March 31, 2017
Warrants outstanding									Warrants exercisable
Range of exercise price			Number outstanding		Weighted average remaining contractual life		Weighted average exercise price		Number exercisable		Weighted average exercise price
$0.25	–	$0.60		27,860,000		2.46	$	0.42		27,860,000	$	0.42

December 31, 2016									December 31, 2016
Warrants outstanding									Warrants exercisable
Range of exercise price			Number outstanding		Weighted average remaining contractual life		Weighted average exercise price		Number exercisable		Weighted average exercise price
$0.25	–	$0.60		27,860,000		2.71	$	0.42		27,860,000	$	0.42

Warrants
Balance at December 31, 2015	22,900,000
Issued	4,970,000
Exercised	-0-
Expired/forfeited	(10,000	)
Balance at December 31, 2016	27,860,000
Issued	-0-
Exercised	-0-
Expired/forfeited	-0-
Balance at March 31, 2017	27,860,000
Warrants exercisable at March 31, 2017	27,860,000

Weighted average fair value of warrants granted during 2017	n/a

Other Comprehensive (Loss)

Due to the availability of net operating losses and related deferred tax valuations, there is no tax effect associated with any component of other comprehensive

(loss). The following table lists the beginning balance, activity and ending balance of the components of accumulated other comprehensive (loss).

	Foreign currency translation			Accumulated other comprehensive (loss)
Balance at December 31, 2015	$	(366,355	)	$	(366,355	)
2016 Activity		(44,150	)		(44,150	)
Balance at December 31, 2016		(410,505	)		(410,505	)
2017 Activity		(2,468	)		(2,468	)
Balance at March 31, 2017	$	(412,973	)	$	(412,973	)

XML 30 R20.htm IDEA: XBRL DOCUMENT

Note 13 - Employee Equity Incentive Plans

3 Months Ended

Mar. 31, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

NOTE

EMPLOYEE EQUITY INCENTIVE PLANS

Stock Option Plan

Description of

Equity Incentive Plan

16,

the Company’s Board of Directors and shareholders approved the OmniComm Systems, Inc.

2016

Equity Incentive Plan (the

“2016

Plan”). The

2016

Plan provides for granting Incentive Stock Options, Nonqualified Stock Options, Stock Appreciation Rights, Restricted Stock Awards, Phantom Stock Unit Awards and Performance Share Units. The

2016

Plan initially provides for the issuance of up to

10,000,000

shares of our common stock for issuance upon awards granted under the

2016

Plan. In addition, the number of shares of common stock available for issuance under the

2016

Plan shall automatically increase on

January

1st

of each year for a period of

nine

(9)

years commencing on

January

2017

and ending on (and including)

January

2025,

in an amount equal to

five

percent

(5%)

of the total number of shares authorized under the

2016

Plan

. Unless earlier terminated by the Board, the

2016

Plan shall terminate on

June

29,

2026.

The maximum term for any option grant under the

Plan is

ten

years from the date of the grant; however, options granted under the

2016

Plan will generally expire

five

years from the date of grant. Options granted to employees generally vest either upon grant or in

two

installments. The

first

vesting, which is equal to

50%

of the granted stock options, usually occurs upon completion of

one

full year of employment from the date of grant and the

second

vesting usually occurs on the

second

anniversary of the date of grant. The vesting period typically begins on the date of hire for new employees and on the date of grant for existing employees. The restrictions on restricted shares granted to employees generally lapse in

three

equal annual installments on the anniversary of the date of grant. Any unvested stock options or restricted shares with restrictions that have not lapsed that are granted under the

2016

Plan are forfeited and expire upon termination of employment.

As of

March

31,

2017,

there were

3,850,000

outstanding options and -

- restricted stock shares that have been granted under the

2016

Plan. At

March

31,

2017,

there were

6,650,000

shares available for grant as options or other forms of share-based compensation under the

2016

Plan.

Description of

2009

Equity Incentive Plan

2009,

the Company

’s Board of Directors and shareholders approved the OmniComm Systems, Inc.

2009

Equity Incentive Plan (the

“2009

Plan”). On

June

16,

2016

the

2009

Plan terminated upon the approval of the

2016

Plan. The

2009

Plan provided for granting Incentive Stock Options, Nonqualified Stock Options, Stock Appreciation Rights, Restricted Stock Awards, Phantom Stock Unit Awards and Performance Share Units. Pursuant to the

2009

Plan,

7,500,000

shares of the Company’s common stock were authorized for issuance.

The maximum term for any option grant under the

2009

Plan

was

ten

years from the date of the grant; however, options granted under the

2009

Plan generally expired

five

years from the date of grant. Options granted to employees generally vested either upon grant or in

two

installments. The

first

vesting, which was equal to

50%

of the granted stock options, usually occurred upon completion of

one

full year of employment from the date of grant and the

second

vesting usually occurred on the

second

anniversary of the date of grant. The vesting period typically began on the date of hire for new employees and on the date of grant for existing employees. The restrictions on restricted shares granted to employees generally lapsed in

three

equal annual installments on the anniversary of the date of grant. Any unvested stock options or restricted shares with restrictions that had not lapsed that were granted under the

2009

Plan were forfeited and expired upon termination of employment.

As of

March

31,

2017,

there were

725,000

outstanding options and

3,876,662

restricted stock shares that have been granted under the

2009

Plan. At

March

31,

2017,

there were -

- shares available for grant as options or other forms of share-based compensation under the

2009

Plan.

The following table summarizes the stock option activity for the Company

’s equity incentive plans:

	Number of options			Weighted average exercise price (per share)		Weighted average remaining contractual term (in years)		Aggregate intrinsic value

Outstanding at December 31, 2015		2,002,500		$	0.14		1.40	$	198,990
Granted		450,000			0.20
Exercised		(1,120,000	)		0.12
Forfeited/cancelled/expired		(107,500	)		0.29

Outstanding at December 31, 2016		1,225,000			0.17		2.62	$	83,425
Granted		3,600,000			0.25
Exercised		-0-			-0-
Forfeited/cancelled/expired		(250,000	)		0.14

Outstanding at March 31, 2017		4,575,000		$	0.24		4.37	$	69,350


Vested and exercisable at March 31, 2017		687,500		$	0.16		1.23	$	60,988

The aggregate intrinsic value in the table above represents the total intrinsic value (the difference between the Company

’s closing stock price at quarter-end and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on

March

31,

2017.

The total number of shares vesting and the fair value of shares vesting for the

three

month periods ended

March

31,

2017

and

March

31,

2016,

respectively, was:

Fair value of options vesting for the three months ended	Number of options vested		Fair value of options vested
March 31, 2017		-0-	$	-0-
March 31, 2016		75,000	$	18,155

Cash received f

or stock option exercises for the

three

month periods ended

March

31,

2017

and

March

31,

2016

was $-

- and $-

-, respectively. Due to the Company’s net loss position,

income tax benefit has been realized during the

three

month periods ended

March

31,

2017

and

March

31,

2016.

The following table summarizes information concerning options outstanding at

March

31,

2017:

Awards breakdown by price range at March 31, 2017
			Outstanding						Vested
Strike price range ($)			Outstanding stock options		Weighted average remaining contractual life		Weighted average outstanding strike price		Vested stock options		Weighted average remaining vested contractual life		Weighted average vested strike price
0.00	to	0.20		650,000		1.57	$	0.16		575,000		1.19	$	0.15
0.21	to	0.30		3,925,000		4.84		0.25		112,500		1.42		0.21
0.31	to	0.50		-0-		0.00		0.00		-0-		0.00		0.00
0.00	to	0.50		4,575,000		4.37	$	0.24		687,500		1.23	$	0.16

The following table summarizes information concerning options outstanding at

December

31,

2016:

Awards breakdown by price range at December 31, 2016
			Outstanding						Vested
Strike price range ($)			Outstanding stock options		Weighted average remaining contractual life		Weighted average outstanding strike price		Vested stock options		Weighted average remaining vested contractual life		Weighted average vested strike price
0.00	to	0.20		850,000		2.15	$	0.15		625,000		1.32	$	0.14
0.21	to	0.30		375,000		3.70		0.23		112,500		1.67		0.21
0.30	to	0.50		-0-		0.00		0.00		-0-		0.00		0.00
0.00	to	0.50		1,225,000		2.62	$	0.17		737,500		1.38	$	0.15

The weighted average fair value (per share) of options granted during the

three

month period ended

March

31,

2017

was

$0.19

and

$0.00

during the

three

month period ended

March

31,

2016

as no options were granted during the

three

month period ending

March

31,

2016.

The Black Scholes option-pricing model was utilized to calculate these values.

Basis for Fair Value Estimate of Share-Based Payments

’s commercialization activities were initiated during the

second

half of

2000.

The Company used a volatility calculation utilizing the Company’s own historical volatility to estimate its future volatility for purposes of valuing the share-based payments that have been granted. Actual volatility, and future changes in estimated volatility,

may

differ substantially from the Company’s current estimates.

The Company utilizes the historical data available regarding employee and director exercise activity to calculate an expected life of the options. The tabl

e below presents the weighted average expected life in years of options granted under the Plan as described above. The risk-free rate of the stock options is based on the U.S. Treasury yield curve in effect at the time of grant, which corresponds with the expected term of the option granted.

Below are the assumptions for the fair value of share-based payments for the

three

month

period ended

March

31,

2017

and the year

December

31,

2016.

	Stock option assumptions for the period ended
Stock option assumptions	March 31, 2017			December 31, 2016
Risk-free interest rate		1.47	%		1.45	%
Expected dividend yield		0.0	%		0.0	%
Expected volatility		150.2	%		155.5	%
Expected life of options (in years)		5			5

The following table summarizes weighted average grant date fair value activity for the Company

’s incentive stock plans:

	Weighted average grant date fair value
	for the three months ended March 31,
	2017		2016
Stock options granted during the period	$	0.19	$	0.00

Stock options vested during the period	$	0.00	$	0.24

Stock options forfeited during the period	$	0.13	$	0.00

A summary of the status of the Company

’s non-vested shares underlying stock options as of

March

31,

2017,

and changes during the

three

month period ended

March

31,

2017

is as follows:

	Shares underlying stock options		Weighted average grant date fair value
Nonvested shares at January 1, 2017		487,500	$	0.20

Nonvested shares at March 31, 2017		3,887,500	$	0.25

As of

March

31,

2017,

$652,007

of total unrecognized compensation cost related to unvested stock options is expected to be recognized over a weighted-average period of

2.0

years.

XML 31 R21.htm IDEA: XBRL DOCUMENT

Note 14 - Subsequent Events

3 Months Ended

Mar. 31, 2017

Subsequent Events [Text Block]

NOTE

SUBSEQUENT EVENTS

Subsequent to

March

31,

2017

the Company repaid

$800,000

on its revolving Line of Credit.

April

2017

the Company renewed the Line of Credit with the Northern Trust Company. The Line of Credit currently matures on

April

2020

and carries a variable interest rate based on the prime rate.

XML 32 R22.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2017

Accounting Policies [Abstract]

Basis of Accounting, Policy [Policy Text Block]

BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION

The Company

’s accounts include those of all its wholly-owned subsidiaries, which are more fully described in the Company’s

2016

Annual Report filed on Form

Consolidation, Policy [Policy Text Block]

UNAUDITED FINANCIAL STATEMENTS

three

month periods ended

March

31,

2017

and

March

31,

2016

are unaudited, but reflect all adjustments (consisting only of normally recurring adjustments) which management considers necessary for a fair presentation of operating results.

The opera

ting results for the

three

month period ended

March

31,

2017

are not necessarily indicative of the results that

may

be expected for the year-ended

December

31,

2017.

-K for the year-ended

December

31,

2016.

Use of Estimates, Policy [Policy Text Block]

ESTIMAT

ES IN FINANCIAL STATEMENTS

may

differ from those estimates.

Reclassification, Policy [Policy Text Block]

Reclassifications

Certain reclassifications have been made in the

2016

financial statements to conform to the

2017

presentation. These reclassifications did not have any effect on our net income/(loss) or shareholders’ deficit.

Foreign Currency Transactions and Translations Policy [Policy Text Block]

foreign currency translation

The financial statements of the Company

’s foreign subsidiaries are translated in accordance with Accounting Standards Codification (“ASC”)

830

30,

Foreign Currency Matters—Translation of Financial Statements

("ASC

830

30").

$2,468

and

$3,156

for the

three

month periods ended

March

31,

2017

and

March

31,

2016,

respectively.

Revenue Recognition, Policy [Policy Text Block]

REVENUE RECOGNITION POLICY

The Company derives revenues from software licenses and services of its EDC products and services whi

ch can be purchased on a stand-alone basis. License revenues are derived principally from the sale of term licenses for the following software products offered by the Company:

TrialMaster, TrialOne

eClinical Suite

and

Promasys.

Service revenues are derived principally from the Company's delivery of the hosted solutions of its

TrialMaster

and

eClinical Suite

software products, and consulting services and customer support, including training, for all of the Company's products.

The Company recognizes revenu

es when all of the following conditions are satisfied:

(1)

there is persuasive evidence of an arrangement;

(2)

the product or service has been provided to the customer;

(3)

the collection of fees is probable; and

(4)

the amount of fees to be paid by the customer is fixed or determinable.

The Company operates in

one

reportable segment which is the delivery of EDC Software and services to clinical trial sponsors. The Company segregates its revenues based on the activity cycle used to generate its revenues.

Accordingly, revenues are currently generated through

four

main activities

, including hosted applications, licensing, professional services and maintenance-related services.

Hosted Application Revenues

The Company offers its

TrialMaster

and

eClinical Suite

software products as hosted application solutions delivered through a standard web-browser, with customer support and training services. The Company's

TrialOne

and

Promasys

solutions are presently available on a technology transfer or off-the shelf basis. To date, hosted applications revenues have been primarily related to

TrialMaster

and

eClinical Suite

Revenues resulting from

TrialMaster

and

eClinical Suite

application hosting services consist of

three

components of services for each clinical trial. The

first

component is comprised of application set up, including design of electronic case report forms and edit checks, installation and server configuration of the system. The

second

component involves application hosting and related support services as well as billable change orders which consist of amounts billed to customers for functionality changes made. The

third

component involves services required to close out, or lock, the database for the clinical trial.

Fees charged for the trial system desig

first

and

third

second

stage are generally billed monthly or quarterly in advance. Revenues resulting from hosting services for the

eClinical Suite

products consist of installation and server configuration, application hosting and related support services. Revenues are recognized ratably over the period of the service.

Licensing Revenues

The Company's software license revenues are earned from the sale of off-the-shelf software. From time-to-time a client might

require significant modification or customization subsequent to delivery to the customer. The Company generally enters into software term licenses for its EDC Software products with its customers for

three

five

days.

The

Company has sold perpetual licenses for EDC Software products in certain situations to existing customers with the option to purchase customer support, and

may,

Professional Services

The Company

may

also enter into arrangements to provide consulting services separate from a li

Pass-through Revenue and

Expense

The Company accounts for pass-through revenue and expense

(reimbursable revenue and reimbursable expense) in accordance with ASC

605

45,

Principal Agent Considerations

(“ASC

605

45”).

In accordance with ASC

605

these amounts are recorded as revenue in the statement of operations with a corresponding expense recorded in cost of goods sold. Pass-through revenues and expenses include amounts associated with

third

-party services provided to our customers by our service and product partners. These

third

-party services are primarily comprised of Interactive Voice and Web Response software services (IVR and IWR), travel and shipping that are incurred on our clients’ behalf.

Maintenance

Revenues

The fees associated with

each business activity for the

three

month periods ended

March

31,

2017

and

March

31,

2016,

respectively

, are:

	For the three months ended
Revenue activity	March 31, 2017		March 31, 2016
Set-up fees	$	1,381,981	$	1,519,334
Change orders		330,411		277,753
Maintenance		1,219,391		1,201,220
Software licenses		1,964,857		1,200,914
Professional services		559,080		652,320
Hosting		279,810		305,970
Total	$	5,735,530	$	5,157,511

Cost of Sales, Policy [Policy Text Block]

COST

OF GOODS SOLD

Cost of goods sold primarily consists of costs related to hosting, maintaining and supporting the Company

’s application suite and delivering professional services and support. These costs include salaries, benefits, and bonuses for the Company’s professional services staff. Cost of

goods sold

also includes outside service provider costs

Cost of

goods sold

is expensed as incurred.

Cash and Cash Equivalents, Policy [Policy Text Block]

CASH AND CASH EQUIVALENTS

Cash equivalents consist of highly liquid, short-term investments with maturities of

days

or less. The carrying amount reported in the accompanying consolidated balance sheets approximates fair value.

Receivables, Policy [Policy Text Block]

ACCOUNTS RECEIVABLE

had recorded an allowance for uncollectible accounts receivable of

$209,179

as of

March

31,

2017

and

$179,813

as of

December

31,

2016.

The following table summarizes activity in the Company's allowance for doubtful accounts for the

three

month

period ended

March

31,

2017

and the year ended

December

31,

2016.

	March 31, 2017		December 31, 2016
Beginning of period	$	179,813	$	116,834
Bad debt expense		29,366		132,767
Write-offs		-0-		(69,788	)
End of period	$	209,179	$	179,813

Concentration Risk, Credit Risk, Policy [Policy Text Block]

Concentration of Credit Risk

Cash and cash equivalents and restricted cash are deposited with major financial institutions and, at times, such balances with any

one

financial institution

may

be in excess of FDIC-insured limits. As of

March

31,

2017,

$337,346

was deposited in excess of FDIC-insured limits. Management believes the risk in these situations to be minimal.

March

31,

2017.

The Company maintains an allowance for doubtful accounts based on accounts past due according to contractual terms and historical collection experience. Actual losses

, when incurred

, are charged to the allowance. The Company's losses related to collection of accounts receivable have consistently been within management's expectations. As of

March

31,

2017,

One customer accounted

for

12%

of our revenues during the

three

month period ended

March

31,

2017

or approximately

$678,000.

One customer accounted for

20%

of our revenues during the

three

month period ended

March

31,

2016

or approximately

$1,037,000.

The following table summarizes the number of customers who individually comprise greater than

10%

of total revenue and/or total accounts receivable and their aggregate percentage of the Company's total revenue and gross accounts receivable for the

three

month periods ended

March

31,

2017

and

March

31,

2016

and the year ended

December

31,

2016.

	Revenues					Accounts receivable
For the period ended	Number of customers		Percentage of total revenues			Number of customers		Percentage of accounts receivable
March 31, 2017		1		12	%		2		30	%
December 31, 2016		1		16	%		2		21	%
March 31, 2016		1		20	%		3		43	%

The table below provides revenues from European customers for the

three

month periods ended

March

31,

2017

and

March

31,

2016.

European revenues
For the three months ended
March 31, 2017					March 31, 2016
European revenues		% of Total revenues			European revenues		% of Total revenues
$	687,209		12	%	$	517,816		10	%

The Company serves all of its hosting customers from

third

-party web hosting facilities located in the United States. The Company does not control the operation of these facilities, and they are vulnerable to damage or interruption. The Company maintains

redundant systems that can be used to provide service in the event the

third

-party web hosting facilities become unavailable, although in such circumstances, the Company's service

may

be interrupted during the transition.

Property, Plant and Equipment, Policy [Policy Text Block]

PROPERTY AND EQUIPMENT

Property

years for leasehold improvements, computers, equipment and furniture and

years for software. Gains or losses on disposal are charged to operations.

Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]

ASSET IMPAIRMENT

Acquisitions and Intangible Assets

We account for acquisitions in accordance with

ASC

805,

Business Combinations

(“ASC

805”)

and

ASC

350,

Intangibles- Goodwill and Other

(“ASC

350”).

Long-lived Assets

We review long-lived assets for impairment whenever events or changes in circumstances indicate that the related carrying amounts

may

Fair Value of Financial Instruments, Policy [Policy Text Block]

FAIR VALUE ME

ASUREMENT

OmniComm

815

Derivatives and Hedging

(“ASC

815”)

ASC

815

820

Fair Value Measurements and Disclosures

(“ASC

820”).

Revenue Recognition, Deferred Revenue [Policy Text Block]

DEFERRED REVENUE

Deferred revenue represents cash advances

and amounts in accounts receivable as of the balance sheet date received in excess of revenue earned on on-going contracts. Payment terms vary with each contract but

may

March

31,

2017,

the Company had

$9,371,694

in deferred revenues relating to contracts for services to be performed over periods ranging from

one

month to

years. The Company had

$7,304,587

in deferred revenues that are expected to be recognized in the next

twelve

fiscal months.

Advertising Costs, Policy [Policy Text Block]

ADVERTISING

Advertising costs are expensed as incurred. Advertising costs were $

171,268

and

$210,954

for the

three

month periods ended

March

31,

2017

and

March

31,

2016,

respectively, and are included under selling, general and administrative expenses in our unaudited condensed consolidated financial statements.

Research, Development, and Computer Software, Policy [Policy Text Block]

RESEARCH AND PRODUCT DEVELOPMENT EXPENSES

Software development costs are expensed as incurred.

ASC

985

20,

Software Industry Costs of Software to Be Sold, Leased or Marketed

(“ASC

985

20”),

985

20.

During the

three

month periods ended

March

31,

2017

and

March

31,

2016

we spent

$778,488

and

$664,605,

third

-party consultants. Research and product development costs are primarily included under Salaries, benefits and related taxes in our Statement of Operations.

Earnings Per Share, Policy [Policy Text Block]

EARNINGS PER SHARE

The Company accounts for Earnings per Share using

ASC

260,

Earnings per Share

(“ASC

260”)

. Unlike diluted earnings per share basic earnings per share excludes any dilutive effects of options, warrants, and convertible securities.

Income Tax, Policy [Policy Text Block]

INCOME TAXES

The Company accounts for income taxes in accordance

with ASC

740,

Income Taxes

(“ASC

740”)

ASC

740

Valuati

on allowances are established

, when necessary

New Accounting Pronouncements, Policy [Policy Text Block]

IMPACT OF NEW ACCOUNTING STANDARDS

During the

first

three

months of

2017,

we adopted the following new accounting pronouncements:

No new applicable pronouncements during the

three

month period ended

March

31,

2017.

Accounting standards-setting organizations frequently issue new or revised accounting rules. We

regularly review all new pronouncements to determine their impact, if any, on our financial statements.

XML 33 R23.htm IDEA: XBRL DOCUMENT

Note 2 - Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2017

Revenue Recognition, Multiple-deliverable Arrangements [Table Text Block]

	For the three months ended
Revenue activity	March 31, 2017		March 31, 2016
Set-up fees	$	1,381,981	$	1,519,334
Change orders		330,411		277,753
Maintenance		1,219,391		1,201,220
Software licenses		1,964,857		1,200,914
Professional services		559,080		652,320
Hosting		279,810		305,970
Total	$	5,735,530	$	5,157,511

Allowance for Credit Losses on Financing Receivables [Table Text Block]

	March 31, 2017		December 31, 2016
Beginning of period	$	179,813	$	116,834
Bad debt expense		29,366		132,767
Write-offs		-0-		(69,788	)
End of period	$	209,179	$	179,813

Schedules of Concentration of Risk, by Risk Factor [Table Text Block]

	Revenues					Accounts receivable
For the period ended	Number of customers		Percentage of total revenues			Number of customers		Percentage of accounts receivable
March 31, 2017		1		12	%		2		30	%
December 31, 2016		1		16	%		2		21	%
March 31, 2016		1		20	%		3		43	%

Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]

European revenues
For the three months ended
March 31, 2017					March 31, 2016
European revenues		% of Total revenues			European revenues		% of Total revenues
$	687,209		12	%	$	517,816		10	%

XML 34 R24.htm IDEA: XBRL DOCUMENT

Note 3 - Earnings (Loss) Per Share (Tables)

3 Months Ended

Mar. 31, 2017

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

Anti-dilutive security	March 31, 2017		March 31, 2016
Preferred stock		-0-		135,135
Employee stock options		4,406,905		2,002,500
Warrants		27,860,000		24,690,000
Convertible notes		15,490,000		15,910,000
Shares issuable for accrued interest		150,940		155,017
Total		47,907,845		42,892,652

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

	For the three months ended
	March 31, 2017						March 31, 2016
	Income/(loss)		Shares		Per-share		Income/(loss)			Shares		Per-share
	numerator		denominator		amount		numerator			denominator		amount
Basic EPS	$	73,974		147,785,621	$	0.00	$	(878,830	)		141,080,292	$	(0.01	)

Effect of dilutive securities		-0-		168,095		-0-		-0-			-0-		-0-

Diluted EPS	$	73,974		147,953,716	$	0.00	$	(878,830	)		141,080,292	$	(0.01	)

XML 35 R25.htm IDEA: XBRL DOCUMENT

Note 4 - Property and Equipment, Net (Tables)

3 Months Ended

Mar. 31, 2017

Property, Plant and Equipment [Table Text Block]

	March 31, 2017						December 31, 2016
	Cost		Accumulated depreciation		Net book value		Cost		Accumulated depreciation		Net book value		Estimated useful life (years)
Computer & office equipment	$	2,185,356	$	1,805,190	$	380,166	$	2,125,067	$	1,761,879	$	363,188		5
Leasehold improvements		116,841		91,940		24,901		114,719		89,789		24,930		5
Computer software		1,928,685		1,755,575		173,110		1,925,462		1,720,399		205,063		3
Office furniture		159,451		117,072		42,379		158,436		114,065		44,371		5
Total	$	4,390,333	$	3,769,777	$	620,556	$	4,323,684	$	3,686,132	$	637,552

XML 36 R26.htm IDEA: XBRL DOCUMENT

Note 5 - Intangible Assets, Net (Tables)

3 Months Ended

Mar. 31, 2017

Schedule of Finite-Lived Intangible Assets [Table Text Block]

	March 31, 2017						December 31, 2016
Asset	Cost		Accumulated amortization		Net book value		Cost		Accumulated amortization		Net book value		Estimated useful life (years)
eClinical Suite customer lists	$	1,392,701	$	1,392,701	$	-0-	$	1,392,701	$	1,392,701	$	-0-		3
Promasys B.V. customer lists		105,711		24,079		81,632		104,163		21,990		82,173		15
Promasys B.V. software code		72,837		49,772		23,065		72,837		46,130		26,707		5
Promasys B.V. URLs/website		53,389		53,389		-0-		52,608		52,608		-0-		3
Total	$	1,624,638	$	1,519,941	$	104,697	$	1,622,309	$	1,513,429	$	108,880

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]

2017	$	16,211
2018		19,187
2019		7,047
2020		7,047
2021		7,047
Thereafter		48,158
Total	$	104,697

XML 37 R27.htm IDEA: XBRL DOCUMENT

Note 6 - Accounts Payable and Accrued Expenses (Tables)

3 Months Ended

Mar. 31, 2017

Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]

Account	March 31, 2017		December 31, 2016
Accounts payable	$	789,898	$	697,060
Accrued payroll and related costs		435,305		886,334
Other accrued expenses		144,986		431,961
Accrued interest		179,579		107,718
Total accounts payable and accrued expenses	$	1,549,768	$	2,123,073

XML 38 R28.htm IDEA: XBRL DOCUMENT

Note 7 - Line of Credit, Notes Payable and Liquidity (Tables)

3 Months Ended

Mar. 31, 2017

Schedule of Debt [Table Text Block]

				Ending		Non related party					Related party
Origination	Maturity	Interest		principal				Long					Long
date	date	rate		March 31, 2017		Current		term			Current		term
2/29/2016	4/1/2019		12%	$	450,000	$	-0-	$	-0-		$	-0-	$	450,000
6/30/2016	4/1/2020		10%		420,000		-0-		420,000			-0-		-0-
6/30/2016	4/1/2020		12%		372,500		-0-		372,500			-0-		-0-
Discount on notes payable							-0-		(420,263	)		-0-		(211,257	)
Total				$	1,242,500	$	-0-	$	372,237		$	-0-	$	238,743

				Ending		Non related party					Related party
Origination	Maturity	Interest		principal				Long					Long
date	date	rate		December 31, 2016		Current		term			Current		term
2/29/2016	4/1/2019		12%	$	450,000	$	-0-	$	-0-		$	-0-	$	450,000
6/30/2016	4/1/2020		10%		420,000		-0-		420,000			-0-		-0-
6/30/2016	4/1/2020		12%		372,500		-0-		372,500			-0-		-0-
Discount on notes payable							-0-		(455,285	)		-0-		(237,664	)
Total				$	1,242,500	$	-0-	$	337,215		$	-0-	$	212,336

XML 39 R29.htm IDEA: XBRL DOCUMENT

Note 8 - Convertible Notes Payable (Tables)

3 Months Ended

Mar. 31, 2017

Schedule of Maturities of Long-term Debt [Table Text Block]

2017	$	50,000
2018		450,000
2019		-0-
2020		6,550,000
Total	$	7,050,000

Convertible Debt [Member]

Schedule of Long-term Debt Instruments [Table Text Block]

						Carrying amount
Date of	Maturity	Interest		Principal at		Short term				Long term
issuance	date	rate		March 31, 2017		Related		Non related		Related		Non related
8/1/1999	6/30/2004		10%	$	50,000	$	-0-	$	50,000	$	-0-	$	-0-
8/29/2008	4/1/2018		10%		150,000		-0-		-0-		-0-		150,000
8/29/2008	4/1/2020		10%		1,770,000		-0-		-0-		1,770,000		-0-
12/16/2008	4/1/2018		12%		200,000		-0-		-0-		-0-		200,000
12/16/2008	4/1/2020		12%		100,000		-0-		-0-		-0-		100,000
12/16/2008	4/1/2020		12%		4,055,000		-0-		-0-		4,055,000		-0-
9/30/2009	4/1/2018		12%		100,000		-0-		-0-		-0-		100,000
9/30/2009	4/1/2020		12%		625,000		-0-		-0-		-0-		625,000
Total				$	7,050,000	$	-0-	$	50,000	$	5,825,000	$	1,175,000

						Carrying amount
Date of	Maturity	Interest		Principal at		Short term				Long term
issuance	date	rate		December 31, 2016		Related		Non related		Related		Non related
8/1/1999	6/30/2004		10%	$	50,000	$	-0-	$	50,000	$	-0-	$	-0-
8/29/2008	4/1/2018		10%		150,000		-0-		-0-		-0-		150,000
8/29/2008	4/1/2020		10%		1,770,000		-0-		-0-		1,770,000		-0-
12/16/2008	4/1/2018		12%		200,000		-0-		-0-		-0-		200,000
12/16/2008	4/1/2020		12%		100,000		-0-		-0-		-0-		100,000
12/16/2008	4/1/2020		12%		4,055,000		-0-		-0-		4,055,000		-0-
9/30/2009	4/1/2018		12%		100,000		-0-		-0-		-0-		100,000
9/30/2009	4/1/2020		12%		625,000		-0-		-0-		-0-		625,000
Total				$	7,050,000	$	-0-	$	50,000	$	5,825,000	$	1,175,000

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21475-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=64930739&loc=d3e28878-108400

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21538-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28541-108399

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28551-108399

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21521-112644

+ Details

XML 40 R30.htm IDEA: XBRL DOCUMENT

Note 9 - Fair Value Measurement (Tables)

3 Months Ended

Mar. 31, 2017

Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]

	Fair value at		Quoted prices in active markets for identical assets/ liabilities		Significant other observable inputs		Significant unobservable inputs
	March 31, 2017		(Level 1)		(Level 2)		(Level 3)
Derivatives: (1) (2)
Conversion feature liability	$	2,134,868	$	-0-	$	-0-	$	2,134,868
Warrant liability		3,796,884		-0-		-0-		3,796,884
Total of derivative liabilities	$	5,931,752	$	-0-	$	-0-	$	5,931,752

	Fair value at		Quoted prices in active markets for identical assets/ liabilities		Significant other observable inputs		Significant unobservable inputs
	December 31, 2016		(Level 1)		(Level 2)		(Level 3)
Derivatives: (1) (2)
Conversion feature liability	$	2,325,730	$	-0-	$	-0-	$	2,325,730
Warrant liability		3,999,362		-0-		-0-		3,999,362
Total of derivative liabilities	$	6,325,092	$	-0-	$	-0-	$	6,325,092

Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]

Significant valuation assumptions for derivative instruments at March 31, 2017
Risk free interest rate	0.82%	to	1.47%
Dividend yield		0.00%
Expected volatility	110.9%	to	129.9%
Expected life (range in years)
Conversion feature liability	1.00	to	3.01
Warrant liability	0.00	to	3.01

Significant valuation assumptions for derivative instruments at December 31, 2016
Risk free interest rate	0.82%	to	1.45%
Dividend yield		0.00%
Expected volatility	117.3%	to	143.8%
Expected life (range in years)
Conversion feature liability	1.25	to	3.25
Warrant liability	0.25	to	3.25

Fair Value Measurements, Nonrecurring [Table Text Block]

	Carrying amount		Carrying amount		Quoted prices in active markets for identical assets/ liabilities		Significant other observable inputs		Significant unobservable inputs
	December 31, 2016		March 31, 2017		(Level 1)		(Level 2)		(Level 3)
Acquired assets (3)
Promasys B.V. customer list (4)	$	82,173	$	81,632	$	-0-	$	-0-	$	136,253
Promasys B.V. software code (4)		26,707		23,065		-0-		-0-		72,943
Promasys B.V. URLs/website (4)		-0-		-0-		-0-		-0-		68,814
Total	$	108,880	$	104,697	$	-0-	$	-0-	$	278,010

Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings [Table Text Block]

	Other income/(expense)
	For the three months ended
	March 31, 2017		March 31, 2016
The net amount of gains/(losses) for the period included in earnings attributable to the unrealized and realized gain/(losses) from changes in derivative liabilities at the reporting date	$	393,340	$	(762,011	)

Total unrealized and realized gains/(losses) included in earnings	$	393,340	$	(762,011	)

Schedule of Derivative Liabilities at Fair Value [Table Text Block]

	Level 3 financial liabilities at fair value
								Net
								purchases,
	Balance,							issuances				Balance,
For the three months ended	beginning			Net realized		Net unrealized		and		Net transfers		end
March 31, 2017	of year			gains/(losses)		gains/(losses)		settlements		in and/or out		of period
Derivatives:
Conversion feature liability	$	(2,325,730	)	$	-0-	$	190,862	$	-0-	$	-0-	$	(2,134,868	)
Warrant liability		(3,999,362	)		-0-		202,478		-0-		-0-		(3,796,884	)
Total of derivative liabilities	$	(6,325,092	)	$	-0-	$	393,340	$	-0-	$	-0-	$	(5,931,752	)

	Level 3 financial liabilities at fair value
									Net
									purchases,
	Balance,								issuances					Balance,
For the year ended	beginning			Net realized		Net unrealized			and			Net transfers		end
December 31, 2016	of year			gains/(losses)		gains/(losses)			settlements			in and/or out		of year
Derivatives:
Conversion feature liability	$	(901,243	)	$	29,108	$	(1,453,595	)	$	-0-		$	-0-	$	(2,325,730	)
Warrant liability		(1,914,923	)		-0-		(1,233,423	)		(851,016	)		-0-		(3,999,362	)
Total of derivative liabilities	$	(2,816,166	)	$	29,108	$	(2,687,018	)	$	(851,016	)	$	-0-	$	(6,325,092	)

Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.

+ References + Details

XML 41 R31.htm IDEA: XBRL DOCUMENT

Note 10 - Commitments and Contingencies (Tables)

3 Months Ended

Mar. 31, 2017

Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]

2017	$	566,546
2018		566,119
2019		421,230
2020		297,570
2021		269,962
Thereafter		310,550
Total	$	2,431,977

Schedule Of Minimum Royalty Payments [Table Text Block]

2017		$	450,000
Total		$	450,000

XML 42 R32.htm IDEA: XBRL DOCUMENT

Note 12 - Stockholders' (Deficit) (Tables)

3 Months Ended

Mar. 31, 2017

Schedule Of Dividends In Arrears [Table Text Block]

	Cumulative arrearage as of				Cumulative arrearage per share as of
	March 31,				March 31,
Series of preferred stock	2017		2016		2017		2016

Series A	$	-0-	$	102,526	$	-0-	$	0.68
Series B		609,887		609,887	$	3.05	$	3.05
Series C		1,472,093		1,472,093	$	4.37	$	4.37
Total preferred stock arrearage	$	2,081,980	$	2,184,506

Schedule of Dividends Payable [Table Text Block]

	Dividends accreted				Dividends per share
	For the three months ended				For the three months ended
	March 31,				March 31,
	2017		2016		2017		2016
Preferred stock dividends in arrears Series A	$	-0-	$	1,870	$	-0-	$	0.012
Preferred stock dividends in arrears Series B	$	-0-	$	-0-	$	-0-	$	-0-
Preferred stock dividends in arrears Series C	$	-0-	$	-0-	$	-0-	$	-0-

Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]

March 31, 2017									March 31, 2017
Warrants outstanding									Warrants exercisable
Range of exercise price			Number outstanding		Weighted average remaining contractual life		Weighted average exercise price		Number exercisable		Weighted average exercise price
$0.25	–	$0.60		27,860,000		2.46	$	0.42		27,860,000	$	0.42

December 31, 2016									December 31, 2016
Warrants outstanding									Warrants exercisable
Range of exercise price			Number outstanding		Weighted average remaining contractual life		Weighted average exercise price		Number exercisable		Weighted average exercise price
$0.25	–	$0.60		27,860,000		2.71	$	0.42		27,860,000	$	0.42

Share-based Compensation, Activity [Table Text Block]

	Weighted average grant date fair value
	for the three months ended March 31,
	2017		2016
Stock options granted during the period	$	0.19	$	0.00

Stock options vested during the period	$	0.00	$	0.24

Stock options forfeited during the period	$	0.13	$	0.00

Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]

	Foreign currency translation			Accumulated other comprehensive (loss)
Balance at December 31, 2015	$	(366,355	)	$	(366,355	)
2016 Activity		(44,150	)		(44,150	)
Balance at December 31, 2016		(410,505	)		(410,505	)
2017 Activity		(2,468	)		(2,468	)
Balance at March 31, 2017	$	(412,973	)	$	(412,973	)

Warrant [Member]

Share-based Compensation, Activity [Table Text Block]

Warrants
Balance at December 31, 2015	22,900,000
Issued	4,970,000
Exercised	-0-
Expired/forfeited	(10,000	)
Balance at December 31, 2016	27,860,000
Issued	-0-
Exercised	-0-
Expired/forfeited	-0-
Balance at March 31, 2017	27,860,000
Warrants exercisable at March 31, 2017	27,860,000

Weighted average fair value of warrants granted during 2017	n/a

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

XML 43 R33.htm IDEA: XBRL DOCUMENT

Note 13 - Employee Equity Incentive Plans (Tables)

3 Months Ended

Mar. 31, 2017

Share-based Compensation, Stock Options, Activity [Table Text Block]

	Number of options			Weighted average exercise price (per share)		Weighted average remaining contractual term (in years)		Aggregate intrinsic value

Outstanding at December 31, 2015		2,002,500		$	0.14		1.40	$	198,990
Granted		450,000			0.20
Exercised		(1,120,000	)		0.12
Forfeited/cancelled/expired		(107,500	)		0.29

Outstanding at December 31, 2016		1,225,000			0.17		2.62	$	83,425
Granted		3,600,000			0.25
Exercised		-0-			-0-
Forfeited/cancelled/expired		(250,000	)		0.14

Outstanding at March 31, 2017		4,575,000		$	0.24		4.37	$	69,350


Vested and exercisable at March 31, 2017		687,500		$	0.16		1.23	$	60,988

Share-based Compensation Arrangements by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding [Table Text Block]

Fair value of options vesting for the three months ended	Number of options vested		Fair value of options vested
March 31, 2017		-0-	$	-0-
March 31, 2016		75,000	$	18,155

Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]

Awards breakdown by price range at March 31, 2017
			Outstanding						Vested
Strike price range ($)			Outstanding stock options		Weighted average remaining contractual life		Weighted average outstanding strike price		Vested stock options		Weighted average remaining vested contractual life		Weighted average vested strike price
0.00	to	0.20		650,000		1.57	$	0.16		575,000		1.19	$	0.15
0.21	to	0.30		3,925,000		4.84		0.25		112,500		1.42		0.21
0.31	to	0.50		-0-		0.00		0.00		-0-		0.00		0.00
0.00	to	0.50		4,575,000		4.37	$	0.24		687,500		1.23	$	0.16

Awards breakdown by price range at December 31, 2016
			Outstanding						Vested
Strike price range ($)			Outstanding stock options		Weighted average remaining contractual life		Weighted average outstanding strike price		Vested stock options		Weighted average remaining vested contractual life		Weighted average vested strike price
0.00	to	0.20		850,000		2.15	$	0.15		625,000		1.32	$	0.14
0.21	to	0.30		375,000		3.70		0.23		112,500		1.67		0.21
0.30	to	0.50		-0-		0.00		0.00		-0-		0.00		0.00
0.00	to	0.50		1,225,000		2.62	$	0.17		737,500		1.38	$	0.15

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

	Stock option assumptions for the period ended
Stock option assumptions	March 31, 2017			December 31, 2016
Risk-free interest rate		1.47	%		1.45	%
Expected dividend yield		0.0	%		0.0	%
Expected volatility		150.2	%		155.5	%
Expected life of options (in years)		5			5

Share-based Compensation, Activity [Table Text Block]

	Weighted average grant date fair value
	for the three months ended March 31,
	2017		2016
Stock options granted during the period	$	0.19	$	0.00

Stock options vested during the period	$	0.00	$	0.24

Stock options forfeited during the period	$	0.13	$	0.00

Schedule of Nonvested Share Activity [Table Text Block]

	Shares underlying stock options		Weighted average grant date fair value
Nonvested shares at January 1, 2017		487,500	$	0.20

Nonvested shares at March 31, 2017		3,887,500	$	0.25

XML 44 R34.htm IDEA: XBRL DOCUMENT

Note 1 - Organization and Nature of Operations (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Research and Development Expense	$ 778,488	$ 664,605

XML 45 R35.htm IDEA: XBRL DOCUMENT

Note 2 - Summary of Significant Accounting Policies (Details Textual)	3 Months Ended		12 Months Ended
	Mar. 31, 2017 USD ($) shares	Mar. 31, 2016 USD ($)	Dec. 31, 2016 USD ($)	Dec. 01, 2016 USD ($)	Jul. 10, 2009 shares
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax	$ (2,468)	$ (3,156)	$ (44,150)
Number of Reportable Segments	1
Number of Revenue Producing Activities	4
Allowance for Doubtful Accounts Receivable, Current	$ 209,179		$ 179,813
Cash, Uninsured Amount	337,346
Revenues	5,735,530	5,157,511
Deferred Revenue	9,371,694
Deferred Revenue, Current	7,304,587			$ 7,250,061
Advertising Expense	171,268	210,954
Research and Development Expense	$ 778,488	$ 664,605
The 2016 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized \| shares	10,000,000
Common Stock Available for Issuance Increasing Period	9 years
Common Stock Available for Issuance, Annual Increase Percent	5.00%
Plan 2009 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized \| shares					7,500,000
Leasehold Improvements Computers Equipment And Furniture [Member]
Property, Plant and Equipment, Useful Life	5 years
Software Development [Member]
Property, Plant and Equipment, Useful Life	3 years
Sales Revenue, Net [Member] \| Customer Concentration Risk [Member]
Concentration Risk, Percentage	12.00%	20.00%	16.00%
Sales Revenue, Net [Member] \| Customer Concentration Risk [Member] \| Customer 1 [Member]
Concentration Risk, Percentage	12.00%	20.00%
Revenues	$ 678,000	$ 1,037,000
Minimum [Member]
Term Of Software License	3 years
Deferred Revenue, Service Contract Term	30 days
Maximum [Member]
Term Of Software License	5 years
Deferred Revenue, Service Contract Term	5 years

XML 46 R36.htm IDEA: XBRL DOCUMENT

Note 2 - Summary of Significant Accounting Policies - Revenue by Business Activity (Details) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Revenues	$ 5,735,530	$ 5,157,511
Set Up Fees [Member]
Revenues	1,381,981	1,519,334
Change Orders [Member]
Revenues	330,411	277,753
Maintenance [Member]
Revenues	1,219,391	1,201,220
Software Licenses [Member]
Revenues	1,964,857	1,200,914
Professional Services [Member]
Revenues	559,080	652,320
Hosting [Member]
Revenues	$ 279,810	$ 305,970

XML 47 R37.htm IDEA: XBRL DOCUMENT

Note 2 - Summary of Significant Accounting Policies - Allowance for Doubtful Account Summary (Details) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Beginning of period	$ 179,813	$ 116,834	$ 116,834
Bad debt expense	29,366	$ (148)	132,767
Write-offs	0		(69,788)
End of period	$ 209,179		$ 179,813

XML 48 R38.htm IDEA: XBRL DOCUMENT

Note 2 - Summary of Significant Accounting Policies - Customer Concentration (Details) - Customer Concentration Risk [Member]	3 Months Ended		12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Sales Revenue, Net [Member]
Number of customers	1	1	1
Concentration risk, percentage	12.00%	20.00%	16.00%
Accounts Receivable [Member]
Number of customers	2	3	2
Concentration risk, percentage	30.00%	43.00%	21.00%

XML 49 R39.htm IDEA: XBRL DOCUMENT

Note 2 - Summary of Significant Accounting Policies - Revenue From European Operations (Details) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
European revenues	$ 5,735,530	$ 5,157,511
Reportable Geographical Components [Member] \| Europe [Member]
European revenues	$ 687,209	$ 517,816
Concentration risk, percentage	12.00%	10.00%

XML 50 R40.htm IDEA: XBRL DOCUMENT

Note 3 - Earnings (Loss) Per Share (Details Textual) - $ / shares	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 01, 2016
Weighted Average Number of Shares Outstanding, Basic	147,785,621	141,080,292
Common Stock, Shares, Outstanding	147,770,249		147,786,917
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	47,907,845	42,892,652
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$ 0.16
Lower Range Limit [Member]
Debt Instrument, Convertible, Conversion Price	0.25
Upper Range Limit [Member]
Debt Instrument, Convertible, Conversion Price	1.25
Lower Range Limit [Member]
Investment Warrants, Exercise Price	0.25
Upper Range Limit [Member]
Investment Warrants, Exercise Price	0.60
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	0.10
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$ 0.25
Restricted Stock [Member]
Common Stock, Shares, Outstanding	1,238,350	1,703,343

XML 51 R41.htm IDEA: XBRL DOCUMENT

Note 3 - Earnings (Loss) Per Share - Reconciliation of Anti-dilutive Securities (Details) - shares	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Anti-dilutive Security (in shares)	47,907,845	42,892,652
Shares Of Preferred Stock [Member]
Anti-dilutive Security (in shares)	0	135,135
Employee Stock Option [Member]
Anti-dilutive Security (in shares)	4,406,905	2,002,500
Warrant [Member]
Anti-dilutive Security (in shares)	27,860,000	24,690,000
Convertible Debt Securities [Member]
Anti-dilutive Security (in shares)	15,490,000	15,910,000
Shares Issuable For Accrued Interest [Member]
Anti-dilutive Security (in shares)	150,940	155,017

XML 52 R42.htm IDEA: XBRL DOCUMENT

Note 3 - Earnings (Loss) Per Share - Computation of Diluted Earnings Per Share (Details) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Basic EPS, Income (loss) numerator	$ 73,974	$ (878,830)
Weighted Average Number of Shares Outstanding, Basic	147,785,621	141,080,292
Basic EPS, Per-share amount (in dollars per share)	$ 0	$ (0.01)
Effect of dilutive securities, Income (loss) numerator	$ 0	$ 0
Effect of dilutive securities, Shares denominator (in shares)	168,095	0
Effect of dilutive securities, Per-share amount (in dollars per share)	$ 0	$ 0
Diluted EPS, Income (loss) numerator	$ 73,974	$ (878,830)
Diluted EPS, Shares denominator (in shares)	147,953,716	141,080,292
Diluted EPS (in dollars per share)	$ 0	$ (0.01)

XML 53 R43.htm IDEA: XBRL DOCUMENT

Note 4 - Property and Equipment, Net (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Depreciation	$ 79,924	$ 70,466

XML 54 R44.htm IDEA: XBRL DOCUMENT

Note 4 - Property and Equipment, Net - Property and Equipment (Details) - USD ($)	3 Months Ended
	Mar. 31, 2017	Dec. 31, 2016	Dec. 01, 2016
Cost	$ 4,390,333	$ 4,323,684
Accumulated Depreciation	3,769,777	3,686,132
Net Book Value	620,556	637,552	$ 637,552
Computer And Office Equipment [Member]
Cost	2,185,356	2,125,067
Accumulated Depreciation	1,805,190	1,761,879
Net Book Value	$ 380,166	363,188
Estimated Useful Lives (Year)	5 years
Leasehold Improvements [Member]
Cost	$ 116,841	114,719
Accumulated Depreciation	91,940	89,789
Net Book Value	$ 24,901	24,930
Estimated Useful Lives (Year)	5 years
Computer Equipment [Member]
Cost	$ 1,928,685	1,925,462
Accumulated Depreciation	1,755,575	1,720,399
Net Book Value	$ 173,110	205,063
Estimated Useful Lives (Year)	3 years
Furniture and Fixtures [Member]
Cost	$ 159,451	158,436
Accumulated Depreciation	117,072	114,065
Net Book Value	$ 42,379	$ 44,371
Estimated Useful Lives (Year)	5 years

XML 55 R45.htm IDEA: XBRL DOCUMENT

Note 5 - Intangible Assets, Net (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Amortization of Intangible Assets	$ 5,403	$ 10,089

XML 56 R46.htm IDEA: XBRL DOCUMENT

Note 5 - Intangible Assets, Net - Intangible Assets (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Mar. 31, 2017	Dec. 01, 2016
Cost	$ 1,622,309	$ 1,624,638
Accumulated Amortization	1,513,429	1,519,941
Net Book Value	108,880	104,697	$ 108,880
eClinical Customer List [Member]
Cost	1,392,701	1,392,701
Accumulated Amortization	1,392,701	1,392,701
Net Book Value	$ 0	0
Finite-Lived Intangible Asset, Useful Life	3 years
Promasys B.V. Customer List [Member]
Cost	$ 104,163	105,711
Accumulated Amortization	21,990	24,079
Net Book Value	$ 82,173	81,632
Finite-Lived Intangible Asset, Useful Life	15 years
Promasys B.V. Software Code [Member]
Cost	$ 72,837	72,837
Accumulated Amortization	46,130	49,772
Net Book Value	$ 26,707	23,065
Finite-Lived Intangible Asset, Useful Life	5 years
Promasys B.V. URLs/Website [Member]
Cost	$ 52,608	53,389
Accumulated Amortization	52,608	53,389
Net Book Value	$ 0	$ 0
Finite-Lived Intangible Asset, Useful Life	3 years

XML 57 R47.htm IDEA: XBRL DOCUMENT

Note 5 - Intangible Assets, Net - Intangible Assets, Future Amortization Expense (Details)	Mar. 31, 2017 USD ($)
2017	$ 16,211
2018	19,187
2019	7,047
2020	7,047
2021	7,047
Thereafter	48,158
Total	$ 104,697

XML 58 R48.htm IDEA: XBRL DOCUMENT

Note 6 - Accounts Payable and Accrued Expenses - Accounts Payable and Accrued Expenses (Details) - USD ($)	Mar. 31, 2017	Dec. 31, 2016	Dec. 01, 2016
Accounts payable	$ 789,898	$ 697,060
Accrued payroll and related costs	435,305	886,334
Other accrued expenses	144,986	431,961
Accrued interest	179,579	107,718
Total accounts payable and accrued expenses	$ 1,549,768	$ 2,123,073	$ 2,123,073

XML 59 R49.htm IDEA: XBRL DOCUMENT

Note 7 - Line of Credit, Notes Payable and Liquidity (Details Textual) - USD ($)	Dec. 05, 2016	Jun. 30, 2016	Feb. 29, 2016	Mar. 18, 2013	Mar. 31, 2017	Dec. 31, 2016	Apr. 01, 2015	Feb. 03, 2015	Dec. 18, 2013
Line of Credit Facility, Maximum Borrowing Capacity				$ 2,000,000				$ 5,000,000	$ 4,000,000
Debt Instrument, Interest Rate, Stated Percentage				2.00%
Debt Instrument, Periodic Payment, Interest				$ 9,500
Long-term Line of Credit					$ 2,700,000
Line of Credit Facility, Interest Rate at Period End					3.00%
Unsecured Debt					$ 1,242,500	$ 1,242,500
Note Payable 17 [Member] \| Chairman and Chief Technology Officer [Member]
Debt Instrument, Interest Rate, Stated Percentage							12.00%
Debt Instrument, Face Amount							$ 20,000
Matures on April 1, 2019 [Member] \| Chief Executive Officer and Director Mr. Wit [Member]
Debt Instrument, Interest Rate, Stated Percentage			12.00%
Debt Instrument, Face Amount			$ 450,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			1,800,000
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 0.25
Extinguishment of Debt, Amount			$ 450,000
Warrants Sold During the Period	1,000,000
Warrants and Rights Outstanding			325,689
Debt Instrument, Fair Value Disclosure			$ 124,311
Amortization Period of Warrant Liabilities			3 years 30 days
Matures April 1, 2020 I [Member] \| Investor [Member]
Debt Instrument, Interest Rate, Stated Percentage		12.00%
Debt Instrument, Face Amount		$ 372,500
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		1,490,000
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.25
Warrants and Rights Outstanding		$ 246,921
Debt Instrument, Fair Value Disclosure		$ 125,579
Amortization Period of Warrant Liabilities		3 years 270 days
Matures April 1, 2020 II [Member] \| Investor [Member]
Debt Instrument, Interest Rate, Stated Percentage		10.00%
Debt Instrument, Face Amount		$ 420,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		1,680,000
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.25
Warrants and Rights Outstanding		$ 278,408
Debt Instrument, Fair Value Disclosure		$ 141,592
Amortization Period of Warrant Liabilities		3 years 270 days

XML 60 R50.htm IDEA: XBRL DOCUMENT

Note 7 - Line of Credit, Notes Payable and Liquidity - Notes Payable (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016	Mar. 18, 2013
Debt Instrument, Interest Rate, Stated Percentage			2.00%
Ending principal	$ 1,242,500	$ 1,242,500
Discount on notes payable
Short-term Debt [Member] \| Related Party [Member]
Ending principal	0	0
Discount on notes payable	0	0
Short-term Debt [Member] \| Non-Related Party [Member]
Ending principal	0	0
Discount on notes payable	0	0
Long-term Debt [Member] \| Related Party [Member]
Ending principal	238,743	212,336
Discount on notes payable	(211,257)	(237,664)
Long-term Debt [Member] \| Non-Related Party [Member]
Ending principal	372,237	337,215
Discount on notes payable	$ (420,263)	$ (455,285)
Notes Payable, Matures April 1, 2019 [Member]
Maturity date	Apr. 01, 2019	Apr. 01, 2019
Debt Instrument, Interest Rate, Stated Percentage	12.00%	12.00%
Ending principal	$ 450,000	$ 450,000
Notes Payable, Matures April 1, 2019 [Member] \| Short-term Debt [Member] \| Non-Related Party Current [Member]
Ending principal	0	0
Notes Payable, Matures April 1, 2019 [Member] \| Short-term Debt [Member] \| Related Party [Member]
Ending principal	0	0
Notes Payable, Matures April 1, 2019 [Member] \| Long-term Debt [Member] \| Non-Related Party Current [Member]
Ending principal	0	0
Notes Payable, Matures April 1, 2019 [Member] \| Long-term Debt [Member] \| Related Party [Member]
Ending principal	$ 450,000	$ 450,000
Notes Payable, Matures April 1, 2020 I [Member]
Maturity date	Apr. 01, 2020	Apr. 01, 2020
Debt Instrument, Interest Rate, Stated Percentage	10.00%	10.00%
Ending principal	$ 420,000	$ 420,000
Notes Payable, Matures April 1, 2020 I [Member] \| Short-term Debt [Member] \| Related Party [Member]
Ending principal	0	0
Notes Payable, Matures April 1, 2020 I [Member] \| Short-term Debt [Member] \| Non-Related Party [Member]
Ending principal	0	0
Notes Payable, Matures April 1, 2020 I [Member] \| Long-term Debt [Member] \| Related Party [Member]
Ending principal	0	0
Notes Payable, Matures April 1, 2020 I [Member] \| Long-term Debt [Member] \| Non-Related Party [Member]
Ending principal	$ 420,000	$ 420,000
Notes Payable, Matures April 1, 2020 II [Member]
Maturity date	Apr. 01, 2020	Apr. 01, 2020
Debt Instrument, Interest Rate, Stated Percentage	12.00%	12.00%
Ending principal	$ 372,500	$ 372,500
Notes Payable, Matures April 1, 2020 II [Member] \| Short-term Debt [Member] \| Related Party [Member]
Ending principal	0	0
Notes Payable, Matures April 1, 2020 II [Member] \| Short-term Debt [Member] \| Non-Related Party [Member]
Ending principal	0	0
Notes Payable, Matures April 1, 2020 II [Member] \| Long-term Debt [Member] \| Related Party [Member]
Ending principal	0	0
Notes Payable, Matures April 1, 2020 II [Member] \| Long-term Debt [Member] \| Non-Related Party [Member]
Ending principal	$ 372,500	$ 372,500

XML 61 R51.htm IDEA: XBRL DOCUMENT

Note 8 - Convertible Notes Payable (Details Textual) - USD ($)							1 Months Ended	3 Months Ended
	Nov. 23, 2015	Nov. 19, 2015	May 01, 2015	Mar. 30, 2011	Sep. 30, 2009	Dec. 31, 1999	Aug. 29, 2008	Mar. 31, 2017	Dec. 31, 2016	Jun. 30, 2016	Feb. 29, 2016	Jun. 30, 2015	May 07, 2015	Apr. 30, 2015	Apr. 27, 2015	Apr. 02, 2015	Jan. 31, 2015	Jul. 31, 2014	Apr. 28, 2014	Apr. 21, 2014	Dec. 31, 2013	Mar. 18, 2013	Mar. 12, 2013	Mar. 06, 2013	Feb. 27, 2013	Feb. 22, 2013	Dec. 16, 2008	Jun. 30, 2008	Jun. 30, 2004
Convertible Notes Payable								$ 7,050,000	$ 7,050,000
Debt Instrument, Interest Rate, Stated Percentage																						2.00%
Director Mr. Wit [Member]
Class of Warrant or Right Cancelled During the Period		1,900,000
Chief Executive Officer [Member]
Debt Instrument, Interest Rate, Stated Percentage											12.00%
Interest Payable											$ 450,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights											1,800,000
Class of Warrant or Right, Exercise Price of Warrants or Rights											$ 0.25
Convertible Notes 10% [Member]
Convertible Notes Payable						$ 862,500
Payments of Debt Issuance Costs						119,625
Proceeds from Issuance of Debt						$ 742,875
Debt Instrument, Interest Rate, Stated Percentage						10.00%
Debt Instrument, Convertible, Conversion Price																													$ 1.25
Debt Conversion, Converted Instrument, Amount								$ 812,500
Debt Conversion, Converted Instrument, Shares Issued								1,495,179
Long-term Debt, Gross								$ 50,000
Interest Payable								$ 89,443
Secured Convertible Debenture [Member]
Convertible Notes Payable					$ 1,400,000
Debt Instrument, Interest Rate, Stated Percentage					12.00%
Proceeds from Issuance of Secured Debt					$ 1,400,000
Repayments of Notes Payable				$ 200,000
Secured Convertible Debenture [Member] \| Extended Maturity Debentures [Member]
Convertible Notes Payable				1,200,000
Secured Convertible Debenture [Member] \| Chief Executive Officer and Director Mr. Wit [Member]
Convertible Notes Payable				$ 1,100,000																						$ 1,100,000
Debt Instrument, Convertible, Conversion Price					$ 0.25
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					5,600,000
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 0.25
Secured Convertible Debenture [Member] \| Chief Executive Officer and Director Mr. Wit [Member] \| Extended Maturity Debentures [Member]
Convertible Notes Payable																	$ 1,100,000
Secured Convertible Debenture [Member] \| Lenders [Member] \| Extended Maturity Debentures [Member]
Convertible Notes Payable										$ 625,000						$ 100,000										1,200,000
Secured Convertible Debenture [Member] \| Director Mr. Wit [Member]
Debt Conversion, Converted Instrument, Amount		$ 475,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		1,900,000
Extinguishment of Debt, Amount		$ 475,000
Stock Issued During Period Converted Cancelled Debt and Cancelled Warrants Shares		1,900,000
Increase (Decrease) in Notes Payable, Related Parties	$ 625,000
Convertible Debentures Issued August 2008 [Member]
Convertible Notes Payable							$ 2,270,000
Convertible Debentures Issued August 2008 [Member] \| Director Mr. Wit [Member] \| Extended Maturity Debentures [Member]
Convertible Notes Payable																	1,770,000									1,770,000
Convertible Debentures Issued August 2008 [Member] \| Chief Officer, Mr. Wit and Mr. Van Kesteren [Member]
Debt Instrument, Interest Rate, Stated Percentage							10.00%
Debt Instrument, Convertible, Conversion Price							$ 0.50
Class of Warrant or Right, Number of Securities Called by Warrants or Rights							4,540,000
Convertible Debentures Issued August 2008 [Member] \| Mr. van Kesteren and Mr. Wit [Member] \| Extended Maturity Debentures [Member]
Convertible Notes Payable					$ 1,920,000																					150,000
Convertible Debentures Issued August 2008 [Member] \| Director Mr. van Kesteren [Member] \| Non-Related Party [Member]
Convertible Notes Payable																		$ 150,000
Convertible Debentures Issued August 2008 [Member] \| Director Mr. van Kesteren [Member] \| Extended Maturity Debentures 2 [Member]
Convertible Notes Payable												$ 150,000
Convertible Debentures [Member] \| Director Mr. Wit [Member]
Convertible Notes Payable																												$ 510,000
Debt Conversion, Converted Instrument, Amount							$ 510,000
Convertible Debentures [Member] \| Chief Officer, Mr. Wit and Mr. Van Kesteren [Member]
Convertible Notes Payable																				$ 150,000
Convertible Debentures [Member] \| Chief Operating Officer [Member]
Convertible Notes Payable														$ 25,000
Debt Instrument, Interest Rate, Stated Percentage														12.00%
Matures April 1, 2020 I [Member] \| Director Mr. Wit [Member]
Convertible Notes Payable										4,055,000
Matures April 1, 2020 I [Member] \| Director Mr. Wit [Member] \| Extended Maturity Debentures 2 [Member]
Convertible Notes Payable										1,770,000
Notes Payable, Matures April 1, 2018 [Member] \| Chief Officer, Mr. Wit and Mr. Van Kesteren [Member]
Convertible Notes Payable										160,000
Notes Payable, Matures April 1, 2018 [Member] \| Chief Officer, Mr. Wit and Mr. Van Kesteren [Member] \| Extended Maturity Debentures 2 [Member]
Convertible Notes Payable										150,000
Convertible Debentures Issued December 2008 [Member]
Convertible Notes Payable																											$ 5,075,000
Convertible Debentures Issued December 2008 [Member] \| Non-Related Party [Member]
Convertible Notes Payable																		$ 160,000
Convertible Debentures Issued December 2008 [Member] \| Extended Maturity Debentures [Member]
Convertible Notes Payable																					$ 360,000
Convertible Debentures Issued December 2008 [Member] \| Lenders [Member]
Convertible Notes Payable												$ 100,000			$ 200,000
Convertible Debentures Issued December 2008 [Member] \| Lenders [Member] \| Extended Maturity Debentures [Member]
Convertible Notes Payable																			$ 100,000				$ 100,000	$ 200,000		4,505,000
Convertible Debentures Issued December 2008 [Member] \| Director Mr. Wit [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		1,680,000
Class of Warrant or Right Cancelled During the Period		1,680,000
Extinguishment of Debt, Amount		$ 420,000
Convertible Debentures Issued December 2008 [Member] \| Director Mr. Wit [Member] \| Extended Maturity Debentures [Member]
Convertible Notes Payable																	$ 4,475,000
Convertible Debentures Issued December 2008 [Member] \| Director Mr. van Kesteren [Member] \| Extended Maturity Debentures [Member]
Convertible Notes Payable			$ 160,000																		$ 160,000
Convertible Debentures Issued December 2008 [Member] \| Chief Executive Officer, Director, Chief Operating Officer, Chairman, Chief Technology Officer, Chief Financial Officer and Directors [Member]
Debt Instrument, Interest Rate, Stated Percentage																											12.00%
Debt Instrument, Convertible, Conversion Price																											$ 0.50
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																											10,150,000
Convertible Debentures Issued December 2008 [Member] \| Officers, Directors and Affiliate [Member] \| Extended Maturity Debentures [Member]
Convertible Notes Payable					$ 4,980,000
Convertible Debentures Issued December 2008 [Member] \| Chief Executive Officer [Member]
Convertible Notes Payable																										4,475,000
Convertible Debentures Issued December 2008 [Member] \| Chief Operating Officer [Member]
Convertible Notes Payable																										25,000
Convertible Debentures Issued December 2008 [Member] \| Chairman and Chief Technology Officer [Member]
Convertible Notes Payable			5,000																							$ 5,000
Related Party Transaction, Amounts of Transaction			$ 5,000
Convertible Debentures Issued December 2008 [Member] \| Former Director [Member]
Convertible Notes Payable													$ 15,000
Convertible Debentures Issued December 2008 [Member] \| Former Director [Member] \| Extended Maturity Debentures [Member]
Convertible Notes Payable																									$ 15,000
Convertible Debentures Issued December 2008 [Member] \| President [Member]
Convertible Notes Payable														$ 25,000
Matures April 1, 2020 II [Member] \| Lenders [Member]
Convertible Notes Payable										$ 100,000

XML 62 R52.htm IDEA: XBRL DOCUMENT

Note 8 - Convertible Notes Payable - Convertible Debt (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016	Dec. 01, 2016	Mar. 18, 2013
Debt Instrument, Interest Rate, Stated Percentage				2.00%
Convertible Notes Payable	$ 7,050,000	$ 7,050,000
Convertible notes payable, short term	50,000		$ 50,000
Convertible notes payable, related parties, long term	5,825,000		5,825,000
Convertible notes payable, long term	1,175,000		$ 1,175,000
Related Party [Member]
Convertible notes payable, short term	0	0
Convertible notes payable, related parties, long term	5,825,000	5,825,000
Non-Related Party [Member]
Convertible notes payable, short term	50,000	50,000
Convertible notes payable, long term	$ 1,175,000	$ 1,175,000
Convertible Notes Payable 10% $50,000 [Member]
Maturity date	Jun. 30, 2004	Jun. 30, 2004
Debt Instrument, Interest Rate, Stated Percentage	10.00%	10.00%
Convertible Notes Payable	$ 50,000	$ 50,000
Convertible Notes Payable 10% $50,000 [Member] \| Related Party [Member]
Convertible notes payable, short term	0	0
Convertible notes payable, related parties, long term	0	0
Convertible Notes Payable 10% $50,000 [Member] \| Non-Related Party [Member]
Convertible notes payable, short term	50,000	50,000
Convertible notes payable, long term	$ 0	$ 0
Convertible Notes Payable 10% $150,000 [Member]
Maturity date	Apr. 01, 2018	Apr. 01, 2018
Debt Instrument, Interest Rate, Stated Percentage	10.00%	10.00%
Convertible Notes Payable	$ 150,000	$ 150,000
Convertible Notes Payable 10% $150,000 [Member] \| Related Party [Member]
Convertible notes payable, short term	0	0
Convertible notes payable, related parties, long term	0	0
Convertible Notes Payable 10% $150,000 [Member] \| Non-Related Party [Member]
Convertible notes payable, short term	0	0
Convertible notes payable, long term	$ 150,000	$ 150,000
Convertible Notes Payable 10% $1,770,000 [Member]
Maturity date	Apr. 01, 2020	Apr. 01, 2020
Debt Instrument, Interest Rate, Stated Percentage	10.00%	10.00%
Convertible Notes Payable	$ 1,770,000	$ 1,770,000
Convertible Notes Payable 10% $1,770,000 [Member] \| Related Party [Member]
Convertible notes payable, short term	0	0
Convertible notes payable, related parties, long term	1,770,000	1,770,000
Convertible Notes Payable 10% $1,770,000 [Member] \| Non-Related Party [Member]
Convertible notes payable, short term	0	0
Convertible notes payable, long term	$ 0	$ 0
Convertible Notes Payable12 Percent, 200,000 [Member]
Maturity date	Apr. 01, 2018	Apr. 01, 2018
Debt Instrument, Interest Rate, Stated Percentage	12.00%	12.00%
Convertible Notes Payable	$ 200,000	$ 200,000
Convertible Notes Payable12 Percent, 200,000 [Member] \| Related Party [Member]
Convertible notes payable, short term	0	0
Convertible notes payable, related parties, long term	0	0
Convertible Notes Payable12 Percent, 200,000 [Member] \| Non-Related Party [Member]
Convertible notes payable, short term	0	0
Convertible notes payable, long term	$ 200,000	$ 200,000
Convertible Notes Payable 12 Percent,100,000 [Member]
Maturity date	Apr. 01, 2020	Apr. 01, 2020
Debt Instrument, Interest Rate, Stated Percentage	12.00%	12.00%
Convertible Notes Payable	$ 100,000	$ 100,000
Convertible Notes Payable 12 Percent,100,000 [Member] \| Related Party [Member]
Convertible notes payable, short term	0	0
Convertible notes payable, related parties, long term	0	0
Convertible Notes Payable 12 Percent,100,000 [Member] \| Non-Related Party [Member]
Convertible notes payable, short term	0	0
Convertible notes payable, long term	$ 100,000	$ 100,000
Convertible Notes Payable 12% $4,055,000 [Member]
Maturity date	Apr. 01, 2020	Apr. 01, 2020
Debt Instrument, Interest Rate, Stated Percentage	12.00%	12.00%
Convertible Notes Payable	$ 4,055,000	$ 4,055,000
Convertible Notes Payable 12% $4,055,000 [Member] \| Related Party [Member]
Convertible notes payable, short term	0	0
Convertible notes payable, related parties, long term	4,055,000	4,055,000
Convertible Notes Payable 12% $4,055,000 [Member] \| Non-Related Party [Member]
Convertible notes payable, short term	0	0
Convertible notes payable, long term	$ 0	$ 0
Convertible Notes Payable, 12%, $100,000 issued 9/30/2009 [Member]
Maturity date	Apr. 01, 2018	Apr. 01, 2018
Debt Instrument, Interest Rate, Stated Percentage	12.00%	12.00%
Convertible Notes Payable	$ 100,000	$ 100,000
Convertible Notes Payable, 12%, $100,000 issued 9/30/2009 [Member] \| Related Party [Member]
Convertible notes payable, short term	0	0
Convertible notes payable, related parties, long term	0	0
Convertible Notes Payable, 12%, $100,000 issued 9/30/2009 [Member] \| Non-Related Party [Member]
Convertible notes payable, short term	0	0
Convertible notes payable, long term	$ 100,000	$ 100,000
Convertible Notes Payable 12% $625,000 [Member]
Maturity date	Apr. 01, 2020	Apr. 01, 2020
Debt Instrument, Interest Rate, Stated Percentage	12.00%	12.00%
Convertible Notes Payable	$ 625,000	$ 625,000
Convertible Notes Payable 12% $625,000 [Member] \| Related Party [Member]
Convertible notes payable, short term	0	0
Convertible notes payable, related parties, long term	0	0
Convertible Notes Payable 12% $625,000 [Member] \| Non-Related Party [Member]
Convertible notes payable, short term	0	0
Convertible notes payable, long term	$ 625,000	$ 625,000

XML 63 R53.htm IDEA: XBRL DOCUMENT

Note 8 - Convertible Notes Payable - Convertible Debt Maturity Payments (Details) - USD ($)	Mar. 31, 2017	Dec. 31, 2016
Total	$ 7,050,000	$ 7,050,000
Convertible Debt [Member]
2017	50,000
2018	450,000
2019	0
2020	6,550,000
Total	$ 7,050,000

XML 64 R54.htm IDEA: XBRL DOCUMENT

Note 9 - Fair Value Measurement (Details Textual)	3 Months Ended
Note 9 - Fair Value Measurement (Details Textual)	Mar. 31, 2017
Minimum [Member]
Finite-Lived Intangible Asset, Useful Life	3 years
Maximum [Member]
Finite-Lived Intangible Asset, Useful Life	15 years

XML 65 R55.htm IDEA: XBRL DOCUMENT

Note 9 - Fair Value Measurement - Fair Value of Liabilities Measured on a Recurring Basis (Details) - USD ($)

Mar. 31, 2017

^[2]

Dec. 31, 2016

^[3]

Fair Value, Inputs, Level 1 [Member]

^[1]

$ 5,931,752

$ 6,325,092

Fair Value, Inputs, Level 2 [Member]

^[1]

Fair Value, Inputs, Level 3 [Member]

^[1]

Conversion Feature Liability [Member]

^[1]

5,931,752

6,325,092

Conversion Feature Liability [Member] | Fair Value, Inputs, Level 1 [Member]

^[1]

2,134,868

2,325,730

Conversion Feature Liability [Member] | Fair Value, Inputs, Level 2 [Member]

^[1]

Conversion Feature Liability [Member] | Fair Value, Inputs, Level 3 [Member]

^[1]

Warrant Liability [Member]

^[1]

2,134,868

2,325,730

Warrant Liability [Member] | Fair Value, Inputs, Level 1 [Member]

^[1]

3,796,884

3,999,362

Warrant Liability [Member] | Fair Value, Inputs, Level 2 [Member]

^[1]

Warrant Liability [Member] | Fair Value, Inputs, Level 3 [Member]

^[1]

^[1]

$ 3,796,884

$ 3,999,362

[1]	The fair value at the measurement date is equal to the carrying value on the balance sheet
[2]	The fair value of the derivative instruments was estimated using the Income Approach and the Black Scholes option pricing model with the following assumptions for the three month period ended March 31, 2017
[3]	The fair value of the derivative instruments was estimated using the Income Approach and the Black Scholes option pricing model with the following assumptions for the year ended December 31, 2016

XML 66 R56.htm IDEA: XBRL DOCUMENT

Note 9 - Fair Value Measurement - Fair Value Assumptions (Details)	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Dividend yield	0.00%	0.00%
Minimum [Member]
Risk free interest rate	0.82%	0.82%
Expected volatility	110.90%	117.30%
Minimum [Member] \| Conversion Feature Liability [Member]
Expected life (Year)	1 year	1 year 91 days
Minimum [Member] \| Warrant Liability [Member]
Expected life (Year)	0 years	91 days
Maximum [Member]
Risk free interest rate	1.47%	1.45%
Expected volatility	129.90%	143.80%
Maximum [Member] \| Conversion Feature Liability [Member]
Expected life (Year)	3 years 3 days	3 years 91 days
Maximum [Member] \| Warrant Liability [Member]
Expected life (Year)	3 years 3 days	3 years 91 days

XML 67 R57.htm IDEA: XBRL DOCUMENT

Note 9 - Fair Value Measurement - Fair Value of Assets Acquired on Non-recurring Basis (Details) - USD ($)

Mar. 31, 2017

Dec. 31, 2016

^[1],[2]

$ 81,632

$ 82,173

^[1],[2]

23,065

26,707

^[1],[2]

Fair Value, Inputs, Level 1 [Member]

^[2]

104,697

$ 108,880

^[1],[2]

^[1],[2]

^[1],[2]

Fair Value, Inputs, Level 2 [Member]

^[2]

^[1],[2]

^[1],[2]

^[1],[2]

Fair Value, Inputs, Level 3 [Member]

^[2]

^[1],[2]

136,253

^[1],[2]

72,943

^[1],[2]

68,814